_unit_id,_created_at,_id,_started_at,_tainted,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,baselinedec,e1,e2,rel-type,sent_id,sentence,term1,term2
788860270,9/15/2015 23:47:33,1739083977,9/15/2015 23:47:14,false,neodev,1,33228343,USA,"","",208.31.49.57,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [ASSOCIATED_WITH] [IS_A] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]
[OTHER]
[NONE]",neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of hee,neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of hee,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 00:15:21,1739091121,9/16/2015 00:14:40,false,elite,1,31722487,USA,NJ,East Brunswick,69.248.85.124,[TREATS],[TREATS],improve cardiac output and stroke volume,N/A,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 01:02:31,1739104065,9/16/2015 01:00:52,false,bitcoinget,1,28503763,USA,CA,San Francisco,107.217.186.64,[NONE],[NONE],N/A,it says refractory to,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 01:08:41,1739107611,9/16/2015 01:05:51,false,clixsense,1,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],short term management,https://app.rnfrstqa.com/settings/sites,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 01:32:19,1739122218,9/16/2015 01:32:06,false,elite,1,30659615,USA,"","",162.250.145.234,[MANIFESTATION],[MANIFESTATION],refractory,N/A,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 01:38:52,1739129682,9/16/2015 01:38:11,false,neodev,1,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],CHF that is refractory to cardiac glycosides (DIGOXIN,CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 01:51:55,1739139864,9/16/2015 01:51:37,false,elite,1,30659677,USA,"","",162.252.172.126,[MANIFESTATION],[MANIFESTATION],refractory,N/A,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 01:52:34,1739140289,9/16/2015 01:52:21,false,bitcoinget,1,31256687,USA,NY,Brooklyn,24.146.181.193,[CAUSES],[CAUSES],refractory,n/a,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 01:52:38,1739140329,9/16/2015 01:51:42,false,points4rewards,1,20306700,USA,WA,Bothell,50.106.46.70,[PREVENTS],[PREVENTS],management,n/a,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 02:15:32,1739158690,9/16/2015 02:14:31,false,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],CHF that refractory to cardiac glycosides (DIGOXIN,contraindicates,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 02:18:01,1739160979,9/16/2015 02:17:46,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],short,N/A,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 02:39:03,1739179961,9/16/2015 02:38:30,false,neodev,1,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [CONTRAINDICATES] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[CONTRAINDICATES]
[NONE]",FVFDV,BTRTB,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 02:40:05,1739181038,9/16/2015 02:39:43,false,elite,1,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],improve,N/A,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 02:41:38,1739182479,9/16/2015 02:40:40,false,neodev,1,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],(DIGOXIN,N/A,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860270,9/16/2015 02:49:48,1739190604,9/16/2015 02:48:56,false,instagc,1,33058612,USA,IL,Glenview,162.229.106.229,[OTHER],[OTHER],refractory,N/A,35,195,152,37,202,RO-may_prevent,820248-FS1,"101 ,   102 ,   104 ,   107 ,   b  CHF  May improve cardiac output and stroke volume and is considered useful in the short term management of severe CHF that is refractory to cardiac glycosides (DIGOXIN and diuretics.",CHF,DIGOXIN
788860271,9/15/2015 23:49:17,1739084376,9/15/2015 23:49:05,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[MANIFESTATION] [CONTRAINDICATES] [LOCATION] [SIDE_EFFECT] [OTHER] [NONE],"[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[OTHER]
[NONE]",casional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obst,casional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obst,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 00:21:28,1739092337,9/16/2015 00:20:11,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was not effective to reduce general,N/A,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 01:08:10,1739107247,9/16/2015 01:07:22,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[NONE],[NONE],N/A,"it says ""not effective"", therefore no relationship",80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 01:19:24,1739114451,9/16/2015 01:18:35,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],reduce general,n/a,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 01:33:49,1739123253,9/16/2015 01:33:36,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],reduce,N/A,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 01:47:35,1739136600,9/16/2015 01:45:42,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[OTHER],[OTHER],FUROSEMIDE was not effective reduce general EDEMA,N/A,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 01:54:10,1739141474,9/16/2015 01:53:56,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],not effective,n/a,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 01:54:21,1739141686,9/16/2015 01:53:56,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],reduce,N/A,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 02:00:42,1739146483,9/16/2015 02:00:01,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[CAUSES],[CAUSES],not effective,n/a,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 02:20:25,1739163241,9/16/2015 02:20:11,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],reduce,N/A,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 02:42:16,1739183144,9/16/2015 02:41:45,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[SYMPTOM] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",HIH,BHYBB ERDDE,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 02:44:43,1739185648,9/16/2015 02:43:30,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],N/A,It was non effective,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 02:46:13,1739187008,9/16/2015 02:45:31,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",FUROSEMIDE,N/A,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 02:51:33,1739192221,9/16/2015 02:51:10,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],acceleration,N/A,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860271,9/16/2015 02:54:50,1739195137,9/16/2015 02:53:57,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[NONE]",no,no,80,33,85,84,43,RO-may_treat,820129-FS1,The occasional administration of FUROSEMIDE was not effective to reduce general EDEMA but served for the acceleration of lymphatic drainage after the release of the thoracic duct obstruction and the patient was extubated uneventfully on the sixth postoperative day.,EDEMA,FUROSEMIDE
788860272,9/15/2015 21:10:34,1739019612,9/15/2015 21:09:59,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[LOCATION],[LOCATION],blocking ARTHRITIS,cares,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:12:51,1739021821,9/15/2015 21:12:31,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],incidence,N/A,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:15:43,1739025242,9/15/2015 21:15:26,false,clixsense,1,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RHEUMATOID,n/a,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:23:14,1739030075,9/15/2015 21:23:00,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[OTHER],[OTHER],reported with,N/A,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:25:35,1739031376,9/15/2015 21:24:40,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]","serious infections neutropenia, ANAKINRA RHEUMATOID ARTHRITIS",treatment,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:44:13,1739041686,9/15/2015 21:42:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER] [SIDE_EFFECT],"[SIDE_EFFECT]
[OTHER]","Increased incidence of serious infections and neutropenia,",N/A,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:44:43,1739041937,9/15/2015 21:44:24,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],reported with,n/a,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:45:10,1739042191,9/15/2015 21:44:52,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[CAUSES],[CAUSES],Increased incidence,n/a,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:54:25,1739046615,9/15/2015 21:54:02,false,neodev,1,33701549,NLD,"","",85.203.17.204,[LOCATION] [PREVENTS] [TREATS] [NONE],"[TREATS]
[PREVENTS]
[LOCATION]
[NONE]",[PREVENTS],N/A,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 21:58:27,1739048374,9/15/2015 21:57:04,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,[CONTRAINDICATES],[CONTRAINDICATES],Increased incidence of serious infections,N/A,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 22:23:38,1739057353,9/15/2015 22:23:19,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CONTRAINDICATES],[CONTRAINDICATES],Increased incidence serious infections,n/a,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 22:27:02,1739058324,9/15/2015 22:26:33,false,instagc,1,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],ANAKINRA in RHEUMATOID ARTHRITIS,n/a,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 22:33:29,1739060604,9/15/2015 22:32:20,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],"Increased incidence without additional benefit,",N/A,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 22:37:31,1739062027,9/15/2015 22:36:48,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],"without benefit, ANAKINRA in RHEUMATOID ARTHRITIS",na,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860272,9/15/2015 22:43:31,1739063834,9/15/2015 22:43:11,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[NONE],[NONE],none,n/a,465,409,485,484,417,RO-may_treat,820009-FS1,"1  Specific Drugs         Drug Interaction Comments   Abatacept Increased incidence of infection and serious infection, without additional clinical benefit, reported with abatacept and TNF blocking agents in rheumatoid arthritis [ 1 , 11 ] Concomitant use not recommended [ 1 , 11 , 15 ]   Anakinra Increased incidence of serious infections and neutropenia, without additional clinical benefit, reported with ANAKINRA and etanercept (another TNF blocking agent) in RHEUMATOID ARTHRITIS [ 1 , 10.",RHEUMATOID ARTHRITIS,ANAKINRA
788860273,9/15/2015 23:48:45,1739084242,9/15/2015 23:48:28,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[MANIFESTATION] [TREATS] [CAUSES] [SYMPTOM] [IS_A] [OTHER] [NONE],"[TREATS]
[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[IS_A]
[OTHER]
[NONE]",sive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA a,sive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA a,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 00:19:22,1739091911,9/16/2015 00:17:42,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]",contributes to the diminished perception of the adrenergic symptoms,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 01:06:49,1739106468,9/16/2015 01:05:20,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",response to,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 01:17:57,1739113760,9/16/2015 01:16:51,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diminished perception,n/a,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 01:33:20,1739122880,9/16/2015 01:33:07,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],contributes,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 01:43:42,1739133646,9/16/2015 01:41:52,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[CAUSES],[CAUSES],Progressive loss epinephrine and GLUCAGON response to hypoglycemia with prolonged duration,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 01:53:38,1739141072,9/16/2015 01:53:15,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],symptoms,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 01:53:40,1739141081,9/16/2015 01:53:30,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[CAUSES],[CAUSES],response,n/a,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 01:57:56,1739144376,9/16/2015 01:56:59,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],contributes,n/a,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 02:19:55,1739162781,9/16/2015 02:19:43,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],symptoms,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 02:41:08,1739181976,9/16/2015 02:40:38,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[PREVENTS] [CAUSES] [NONE],"[PREVENTS]
[CAUSES]
[NONE]",YHBH,VGVGHXRFXC TGYVY,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 02:42:34,1739183424,9/16/2015 02:41:44,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],Progressive loss of GLUCAGON adrenergic symptoms HYPOGLYCEMIA,symptoms,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 02:44:39,1739185623,9/16/2015 02:44:06,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[TREATS],[TREATS],GLUCAGON,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 02:50:43,1739191582,9/16/2015 02:50:15,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],increases,N/A,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860273,9/16/2015 02:53:53,1739194369,9/16/2015 02:53:33,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [TREATS] [NONE],"[TREATS]
[PREVENTS]
[NONE]",no,no,179,38,71,190,46,RO-may_treat,820092-FS1,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
788860274,9/15/2015 22:24:45,1739057653,9/15/2015 22:24:26,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],provide better control,n/a,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 22:28:13,1739058716,9/15/2015 22:27:55,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],INSULIN with TYPE 2 DIABETES,n/a,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 22:37:08,1739061880,9/15/2015 22:36:07,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",glycemic control,N/A,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 22:39:57,1739062900,9/15/2015 22:39:19,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],INSULIN in subjects with TYPE 2 DIABETES,na,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 22:44:54,1739064269,9/15/2015 22:44:34,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],in subjects with,n/a,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 22:49:52,1739065787,9/15/2015 22:49:01,false,prodege,1,34294822,USA,TX,Allen,99.7.230.126,[TREATS],[TREATS],provide control,N/A,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 22:52:03,1739066430,9/15/2015 22:50:34,false,clixsense,1.0,6330007,AUS,"","",101.178.25.217,[TREATS],[TREATS],provide better,n/a,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 22:54:55,1739067903,9/15/2015 22:54:15,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],provide better postprandial glycemic control,N/A,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 23:16:02,1739074830,9/15/2015 23:15:18,false,clixsense,1,31580375,GBR,H4,Leicester,5.67.162.207,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",postprandial glycemic control,n/a,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 23:32:57,1739080074,9/15/2015 23:31:44,false,elite,1.0,31722487,USA,UT,Providence,206.190.129.237,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",in subjects with,N/A,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 23:35:29,1739080719,9/15/2015 23:34:49,false,neodev,1.0,31294288,USA,UT,Providence,206.190.129.237,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",in subjects with,N/A,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/15/2015 23:40:25,1739082162,9/15/2015 23:39:45,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[CAUSES] [PREVENTS] [LOCATION] [MANIFESTATION] [PART_OF] [NONE],"[PREVENTS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[PART_OF]
[NONE]",good,sulin analog combinations provide better postprandial glycemic control compared with 70/30 reg,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/16/2015 00:04:39,1739088440,9/16/2015 00:03:12,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",postprandial glycemic control,N/A,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/16/2015 00:20:17,1739092033,9/16/2015 00:19:39,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],in subjects with,N/A,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860274,9/16/2015 00:45:00,1739098059,9/16/2015 00:42:24,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],postprandial glycemic control,I didn't select none,149,124,164,163,131,RO-may_treat,820093-FS1,These new biphasic insulin analog combinations provide better postprandial glycemic control compared with 70/30 regular/NPH INSULIN in subjects with TYPE 2 DIABETES ( 126.,TYPE 2 DIABETES,INSULIN
788860275,9/15/2015 23:49:03,1739084318,9/15/2015 23:48:48,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [SYMPTOM] [CONTRAINDICATES] [PART_OF] [OTHER] [NONE],"[PREVENTS]
[SYMPTOM]
[CONTRAINDICATES]
[PART_OF]
[OTHER]
[NONE]","multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE","multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE",178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 00:20:06,1739091997,9/16/2015 00:19:28,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",conducted to evaluate in patients with,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 01:07:20,1739106740,9/16/2015 01:06:50,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",clinical efficacy,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 01:18:33,1739114041,9/16/2015 01:17:58,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],low doses of inhaled,n/a,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 01:33:34,1739123101,9/16/2015 01:33:23,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],patients with,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 01:45:40,1739135088,9/16/2015 01:43:43,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],doses of inhaled FLUTICASONE PROPIONATE in patients with MILD MODERATE ASTHMA,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 01:53:53,1739141302,9/16/2015 01:53:40,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 01:53:54,1739141308,9/16/2015 01:53:40,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 02:00:00,1739145951,9/16/2015 01:57:57,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],evaluate,n/a,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 02:20:09,1739162946,9/16/2015 02:19:56,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[LOCATION],[LOCATION],in,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 02:41:42,1739182511,9/16/2015 02:41:11,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [MANIFESTATION] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[NONE]",VGHB,CDXSX JKIOK,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 02:43:28,1739184404,9/16/2015 02:42:35,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],FLUTICASONE PROPIONATE MILD TO MODERATE ASTHMA,treats,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 02:45:29,1739186359,9/16/2015 02:44:42,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],FLUTICASONE PROPIONATE,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 02:51:08,1739191830,9/16/2015 02:50:45,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],doses,N/A,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860275,9/16/2015 02:54:17,1739194599,9/16/2015 02:53:39,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,Fluticasone treats the asthma,178,133,201,200,155,RO-may_prevent,820372-FS1,"A multicenter, double blind, parallel group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled FLUTICASONE PROPIONATE (FP) in patients with MILD TO MODERATE ASTHMA",MILD TO MODERATE ASTHMA,FLUTICASONE PROPIONATE
788860276,9/16/2015 03:05:45,1739205124,9/16/2015 03:05:22,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,Asdociate,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 03:11:25,1739209981,9/16/2015 03:10:53,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,thyroxine treats hypothyroidism,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 03:30:44,1739227788,9/16/2015 03:29:14,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HYPOTHYROIDISM,NONE,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 03:34:42,1739231515,9/16/2015 03:34:08,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],treatment with,N/A,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 03:43:27,1739239911,9/16/2015 03:42:57,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[SIDE_EFFECT],[SIDE_EFFECT],resolved after months' replacement treatment with,N/A,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 04:05:05,1739259410,9/16/2015 04:04:45,false,gifthunterclub,1,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],HYPOTHYROIDISM replacement treatment with THYROXINE,N/A,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 04:07:26,1739261569,9/16/2015 04:06:46,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",associated with treatment with,n/a,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 04:17:33,1739271347,9/16/2015 04:17:20,false,neodev,1,33373894,USA,MI,Ann Arbor,35.2.200.96,[CAUSES] [MANIFESTATION] [IS_A] [NONE],"[CAUSES]
[MANIFESTATION]
[IS_A]
[NONE]",none,none,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 04:29:32,1739282820,9/16/2015 04:29:21,false,elite,1,33798502,USA,VA,Manassas,207.244.79.135,[TREATS],[TREATS],HYPOTHYROIDISM,It makes sense,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 04:32:38,1739286408,9/16/2015 04:31:32,false,clixsense,1,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [TREATS],"[TREATS]
[NONE]",treatment,N/A,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 04:53:25,1739307872,9/16/2015 04:52:40,false,neodev,1,33739744,USA,VA,Manassas,207.244.83.121,[NONE] [OTHER],"[OTHER]
[NONE]",N/a,I did not find any relationship,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 05:13:33,1739328431,9/16/2015 05:12:59,false,elite,1,29216801,USA,"","",172.164.36.118,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 05:16:03,1739330981,9/16/2015 05:15:46,false,elite,1,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],resolved replacement treatment with,n/a,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 05:16:57,1739331931,9/16/2015 05:16:37,false,clixsense,1,19294877,USA,MA,Boston,71.174.187.97,[TREATS],[TREATS],HYPOTHYROIDISM resolved after 6 months' replacement treatment with THYROXINE,n/a,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860276,9/16/2015 05:22:35,1739337054,9/16/2015 05:19:48,false,gifthunterclub,1,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,63,135,77,76,144,RO-may_prevent,820254-FS1,A 10 year old girl with hypertrichosis associated with primary HYPOTHYROIDISM that resolved after 6 months' replacement treatment with THYROXINE is reported.,HYPOTHYROIDISM,THYROXINE
788860277,9/16/2015 02:49:35,1739190436,9/16/2015 02:49:09,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[LOCATION] [MANIFESTATION] [ASSOCIATED_WITH] [NONE],"[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[NONE]",BJNJKHB,VHJVG HJGVHYVGB,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 02:58:47,1739198627,9/16/2015 02:57:55,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[PREVENTS],[PREVENTS],ANTHELMINTIC WORM,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 03:04:06,1739203570,9/16/2015 03:03:44,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],reduce,Treat,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 03:07:30,1739206578,9/16/2015 03:06:33,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[OTHER],[OTHER],be resistant,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 03:27:02,1739224339,9/16/2015 03:26:19,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ANTHELMINTIC,NONE,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 03:31:46,1739228732,9/16/2015 03:31:11,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was found to be resistant,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 03:41:20,1739238012,9/16/2015 03:40:40,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[OTHER],[OTHER],failing to reduce,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 04:03:20,1739258060,9/16/2015 04:02:50,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],ANTHELMINTIC failing to reduce WORM burdens.,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 04:03:50,1739258371,9/16/2015 04:03:16,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS],[PREVENTS],reduce,n/a,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 04:15:54,1739269953,9/16/2015 04:15:30,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[SYMPTOM] [PREVENTS] [ASSOCIATED_WITH] [PART_OF] [NONE],"[PREVENTS]
[SYMPTOM]
[ASSOCIATED_WITH]
[PART_OF]
[NONE]",nothing,nothing,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 04:26:12,1739279419,9/16/2015 04:24:21,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [OTHER],"[OTHER]
[NONE]",failing to significantly reduce,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 04:28:32,1739281742,9/16/2015 04:28:19,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,[PREVENTS],[PREVENTS],Haemonchus,It makes sense,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 04:50:18,1739304699,9/16/2015 04:50:04,false,neodev,1.0,33739744,USA,VA,Manassas,207.244.83.121,[NONE] [OTHER],"[OTHER]
[NONE]",N/a,found no relationship,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 05:05:19,1739320116,9/16/2015 05:04:34,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[OTHER] [ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]
[OTHER]",ANTHELMINTIC failing to significantly reduce WORM burdens.,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860277,9/16/2015 05:10:06,1739325033,9/16/2015 05:09:22,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],failing to reduce,N/A,177,132,181,180,144,RO-may_prevent,820375-FS1,A strain of Haemonchus contortus (CAVR) isolated in Australia was found to be resistant to ivermectin (IVM) with 0.4 mg kg 1 of the ANTHELMINTIC failing to significantly reduce WORM burdens.,WORM,ANTHELMINTIC
788860278,9/15/2015 23:45:42,1739083486,9/15/2015 23:45:24,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[CAUSES] [ASSOCIATED_WITH] [MANIFESTATION] [LOCATION] [SIDE_EFFECT] [NONE],"[CAUSES]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]",bad,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 00:09:46,1739089801,9/16/2015 00:09:13,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",on the development of,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 00:56:56,1739101274,9/16/2015 00:56:28,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",The effect of,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 00:59:37,1739102674,9/16/2015 00:58:56,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CAUSES],[CAUSES],effect on the development,n/a,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 01:28:22,1739119907,9/16/2015 01:27:20,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],effect of IRBESARTAN DIABETIC NEPHROPATHY patients,"The effects were studied, but told of no results",47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 01:30:32,1739121024,9/16/2015 01:30:18,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],development,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 01:31:25,1739121544,9/16/2015 01:30:44,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[SIDE_EFFECT],[SIDE_EFFECT],effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY,effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 01:44:52,1739134556,9/16/2015 01:44:45,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],development,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 01:47:48,1739136798,9/16/2015 01:47:17,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[PART_OF],[PART_OF],effect,n/a,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 01:49:31,1739138038,9/16/2015 01:49:11,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],development,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 01:51:02,1739139200,9/16/2015 01:50:45,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[SYMPTOM],[SYMPTOM],development,n/a,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 02:16:28,1739159633,9/16/2015 02:16:14,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],development,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 02:35:09,1739176424,9/16/2015 02:33:51,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],development,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 02:35:41,1739176958,9/16/2015 02:35:03,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[NONE]",CACAROTO,SON GOKU,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860278,9/16/2015 02:35:41,1739176974,9/16/2015 02:34:29,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[MANIFESTATION],[MANIFESTATION],NEPHROPATHY,N/A,47,14,67,66,24,RO-may_treat,820014-FS1,The effect of IRBESARTAN on the development of DIABETIC NEPHROPATHY in patients with type 2 diabetes.,DIABETIC NEPHROPATHY,IRBESARTAN
788860279,9/16/2015 01:57:41,1739144228,9/16/2015 01:57:29,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[TREATS],[TREATS],use,n/a,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 02:23:53,1739166303,9/16/2015 02:23:24,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 02:48:41,1739189540,9/16/2015 02:48:17,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[ASSOCIATED_WITH] [SYMPTOM] [PREVENTS] [NONE],"[PREVENTS]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]",VHJV,BHVH XDRFDDF,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 02:56:59,1739197055,9/16/2015 02:55:52,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[CONTRAINDICATES],[CONTRAINDICATES],MAGNESIUM SULFATE,N/A,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 02:59:48,1739199627,9/16/2015 02:59:36,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],in,N/A,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 03:03:14,1739202785,9/16/2015 03:02:40,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[PART_OF],[PART_OF],ingrained,Part of,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 03:05:17,1739204712,9/16/2015 03:03:42,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,magnesium sulfate is used for preeclampsia,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 03:06:05,1739205447,9/16/2015 03:05:41,false,neodev,1.0,34431172,USA,NY,New York,162.243.160.236,[CAUSES] [LOCATION] [NONE],"[CAUSES]
[LOCATION]
[NONE]",no,no,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 03:25:31,1739222936,9/16/2015 03:24:42,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[LOCATION],[LOCATION],PREECLAMPSIA,NONE,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 03:30:26,1739227480,9/16/2015 03:29:37,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],the routine use of,N/A,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 03:40:18,1739237095,9/16/2015 03:39:55,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],use for seizure prophylaxis,N/A,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 04:02:22,1739257154,9/16/2015 04:02:00,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],routine use MAGNESIUM SULFATE for women with PREECLAMPSIA,N/A,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 04:02:24,1739257166,9/16/2015 04:01:10,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",use of,n/a,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 04:15:11,1739269181,9/16/2015 04:14:11,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[OTHER]
[NONE]",ninguno,ninguno,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860279,9/16/2015 04:27:10,1739280511,9/16/2015 04:26:12,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[DIAGNOSE_BY_TEST_OR_DRUG] [NONE] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[NONE]",routine use of,N/A,86,30,98,97,47,RO-may_treat,820135-FS1,"In the US, the routine use of MAGNESIUM SULFATE for seizure prophylaxis in women with PREECLAMPSIA is an ingrained obstetric practice.",PREECLAMPSIA,MAGNESIUM SULFATE
788860280,9/15/2015 22:52:51,1739067007,9/15/2015 22:52:41,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[NONE],[NONE],n/a,n/a,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/15/2015 22:58:58,1739069043,9/15/2015 22:58:33,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],more active against,N/A,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/15/2015 23:43:08,1739082886,9/15/2015 23:42:55,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [LOCATION] [IS_A] [SYMPTOM] [MANIFESTATION] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[MANIFESTATION]
[IS_A]
[NONE]",bad,inson's disease Lisuride for levodopa induced complications in Parkinson's disease Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease Non pharmacological therapies for dysphagia in Parkinson's disease Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE Pramipexole for levodopa induced complications in Parkinson's disease Pramipexole versus bromocr,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/15/2015 23:56:06,1739086467,9/15/2015 23:54:55,false,neodev,1.0,31294288,USA,NJ,East Brunswick,69.248.85.124,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",is more active against,N/A,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/15/2015 23:56:32,1739086591,9/15/2015 23:55:59,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",more active against,N/A,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 00:22:34,1739092623,9/16/2015 00:22:21,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],against,N/A,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 00:48:56,1739098914,9/16/2015 00:48:28,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",more active against,N/A,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 00:53:00,1739100178,9/16/2015 00:52:18,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],more active against,n/a,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 00:59:36,1739102676,9/16/2015 00:57:30,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 01:18:20,1739113949,9/16/2015 01:17:20,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],(SODIUM NEDOCROMIL more active against ATOPIC BRONCHIAL ASTHMA,treats,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 01:18:48,1739114121,9/16/2015 01:17:12,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],(SODIUM NEDOCROMIL is active against ATOPIC BRONCHIAL ASTHMA,SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 01:22:41,1739116411,9/16/2015 01:22:19,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,[NONE],[NONE],none,n/a,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 01:25:32,1739118143,9/16/2015 01:24:09,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(SODIUM NEDOCROMIL ATOPIC BRONCHIAL ASTHMA,n/a,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 01:26:04,1739118529,9/16/2015 01:25:45,false,neodev,1.0,33739202,USA,MS,Madison,75.65.195.220,[LOCATION] [SIDE_EFFECT] [PART_OF] [OTHER] [NONE],"[LOCATION]
[SIDE_EFFECT]
[PART_OF]
[OTHER]
[NONE]",nose,omplicaciones en el Parkinson enfermedad Lisuride de levodopa inducida complicaciones en el Parkinson enfermedad Lisuride frente bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad No farmacológicas terapias para la disfagia en el Parkinson enfermedad La pergolida para levodopa INDUCIDA COMPLICACIONES en de Parkinson enfermedad La pergolida en comparación con la bromocriptina para levodopa inducida motor complicaciones en DE PARKINSON ENFERMEDAD El pramipexol de levodopa inducida complicaciones en el Parkinson enfermedad El pramipexol en comparación con la bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol de levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol frente bromocriptina para levodopa inducida complicaciones en el Parkinson.,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860280,9/16/2015 01:28:36,1739119986,9/16/2015 01:28:22,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],against,N/A,132,72,156,154,90,RO-may_prevent,820257-FS1,"As shown by clinical, allergological and immunological findings, tailed (SODIUM NEDOCROMIL compared to intal is more active against ATOPIC BRONCHIAL ASTHMA complicated by obstructive bronchitis.",ATOPIC BRONCHIAL ASTHMA,(SODIUM NEDOCROMIL
788860281,9/15/2015 22:27:03,1739058325,9/15/2015 22:26:28,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have,n/a,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/15/2015 22:45:50,1739064662,9/15/2015 22:45:38,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[SIDE_EFFECT],[SIDE_EFFECT],elevated plasma levels,n/a,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/15/2015 22:57:00,1739068455,9/15/2015 22:56:22,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[SYMPTOM],[SYMPTOM],commonly have,N/A,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/15/2015 22:57:29,1739068626,9/15/2015 22:54:31,false,clixsense,1.0,6330007,AUS,"","",101.178.25.217,[SYMPTOM],[SYMPTOM],have elevated levels TRIIODOTHYRONINE,n/a,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/15/2015 23:18:45,1739075575,9/15/2015 23:17:31,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have GOITERS and TRIIODOTHYRONINE,n/a,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/15/2015 23:38:29,1739081631,9/15/2015 23:37:04,false,neodev,1.0,31294288,USA,UT,Providence,206.190.129.237,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",elevated plasma levels of total,N/A,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/15/2015 23:42:08,1739082651,9/15/2015 23:41:38,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",bad,"are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albei",52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/15/2015 23:54:07,1739085868,9/15/2015 23:53:43,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",elevated plasma levels,N/A,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/16/2015 00:21:21,1739092299,9/16/2015 00:21:03,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[OTHER],[OTHER],and,N/A,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/16/2015 00:46:56,1739098489,9/16/2015 00:45:19,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[NONE],[NONE],N/A,a list of things connected by AND,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/16/2015 00:47:36,1739098640,9/16/2015 00:44:53,false,clixsense,1.0,22947672,GBR,H9,London,146.198.116.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"GOITERS elevated plasma levels and TRIIODOTHYRONINE normal thyroid hormone metabolism,",n/a,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/16/2015 00:49:34,1739099089,9/16/2015 00:47:48,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CAUSES],[CAUSES],elevated plasma levels of TRIIODOTHYRONINE,n/a,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/16/2015 00:51:21,1739099680,9/16/2015 00:49:29,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],Affected subjects have GOITERS of TRIIODOTHYRONINE,manifestation,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/16/2015 00:52:00,1739099869,9/16/2015 00:49:19,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860281,9/16/2015 01:15:18,1739112226,9/16/2015 01:14:34,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE,have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE,52,115,59,58,131,RO-may_treat,820137-FS1,"Affected subjects are commonly eumetabolic and have GOITERS elevated plasma levels of total and free thyroxine and TRIIODOTHYRONINE normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone.",GOITERS,TRIIODOTHYRONINE
788860282,9/16/2015 01:57:17,1739143937,9/16/2015 01:57:02,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[PART_OF],[PART_OF],and,n/a,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 02:02:32,1739147925,9/16/2015 02:02:02,false,elite,1.0,30659677,USA,"","",162.252.172.126,[LOCATION],[LOCATION],and,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 02:06:25,1739151389,9/16/2015 02:05:52,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[CAUSES],[CAUSES],evidence,n/a,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 02:23:08,1739165725,9/16/2015 02:22:54,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 02:47:45,1739188486,9/16/2015 02:47:17,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",BJHB,BNJHB DXF,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 02:54:59,1739195236,9/16/2015 02:54:09,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[SYMPTOM],[SYMPTOM],FACTOR VIII/VON WILLEBRAND ANTIGEN,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 02:59:14,1739199131,9/16/2015 02:58:47,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],disease,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 03:02:14,1739201672,9/16/2015 03:01:34,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 03:03:14,1739202787,9/16/2015 03:02:35,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII and FACTOR VIII/VON WILLEBRAND ANTIGEN,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 03:05:21,1739204811,9/16/2015 03:05:08,false,neodev,1.0,34431172,USA,NY,New York,162.243.160.236,[NONE] [SYMPTOM],"[SYMPTOM]
[NONE]",no,no,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 03:23:49,1739221367,9/16/2015 03:23:02,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Willebrand disease,NONE,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 03:28:33,1739225645,9/16/2015 03:27:42,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[MANIFESTATION],[MANIFESTATION],evidence of an abnormal molecular,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 03:39:40,1739236394,9/16/2015 03:39:08,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Patients with and,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 04:00:17,1739255071,9/16/2015 03:59:36,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],with activity,n/a,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860282,9/16/2015 04:01:39,1739256520,9/16/2015 04:00:43,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations,N/A,43,124,75,94,158,RO-may_treat,820017-FS1,"100 ,   111 ,   114 ,   116  Patients with SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE WITH FACTOR VIII coagulant activity and FACTOR VIII/VON WILLEBRAND ANTIGEN concentrations   111 ,   116 ,   a  Not  indicated for patients with severe type 1 von Willebrand disease or when there is evidence of an abnormal molecular form of factor VIII antigen.",SEVERE HOMOZYGOUS VON WILLEBRAND DISEASE,FACTOR VIII/VON WILLEBRAND ANTIGEN
788860283,9/15/2015 22:53:01,1739067074,9/15/2015 22:52:52,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],treatment,n/a,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/15/2015 22:59:32,1739069217,9/15/2015 22:58:59,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],in the treatment of,N/A,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/15/2015 23:43:29,1739082988,9/15/2015 23:43:11,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [LOCATION] [IS_A] [OTHER] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[IS_A]
[OTHER]
[NONE]",bad,ubcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 00:01:41,1739087734,9/16/2015 00:01:03,false,neodev,1.0,31294288,USA,NJ,East Brunswick,69.248.85.124,[TREATS],[TREATS],in treatment of,N/A,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 00:03:36,1739088143,9/16/2015 00:03:12,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[TREATS],[TREATS],in the treatment of,N/A,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 00:22:44,1739092665,9/16/2015 00:22:34,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],in the treatment of,N/A,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 00:49:27,1739099058,9/16/2015 00:48:58,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment of,N/A,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 00:53:31,1739100281,9/16/2015 00:53:00,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],treatment,n/a,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 01:01:08,1739103475,9/16/2015 00:59:37,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 01:19:00,1739114228,9/16/2015 01:18:21,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],HEPARIN the treatment of THROMBOEMBOLISM,Treats,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 01:19:56,1739114825,9/16/2015 01:18:49,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],heparin can substitute the intravenous form of HEPARIN treatment of THROMBOEMBOLISM,heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 01:22:57,1739116527,9/16/2015 01:22:42,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,[NONE],[NONE],none,n/a,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 01:26:17,1739118689,9/16/2015 01:26:05,false,neodev,1.0,33739202,USA,MS,Madison,75.65.195.220,[MANIFESTATION] [SIDE_EFFECT] [NONE] [OTHER],"[MANIFESTATION]
[SIDE_EFFECT]
[OTHER]
[NONE]",nose,omplicaciones en el Parkinson enfermedad Lisuride de levodopa inducida complicaciones en el Parkinson enfermedad Lisuride frente bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad No farmacológicas terapias para la disfagia en el Parkinson enfermedad La pergolida para levodopa INDUCIDA COMPLICACIONES en de Parkinson enfermedad La pergolida en comparación con la bromocriptina para levodopa inducida motor complicaciones en DE PARKINSON ENFERMEDAD El pramipexol de levodopa inducida complicaciones en el Parkinson enfermedad El pramipexol en comparación con la bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol de levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol frente bromocriptina para levodopa inducida complicaciones en el Parkinson.,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 01:26:17,1739118690,9/16/2015 01:25:32,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[TREATS],[TREATS],treatment,n/a,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860283,9/16/2015 01:28:49,1739120052,9/16/2015 01:28:38,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,125,68,140,139,75,RO-may_prevent,820381-FS1,Subcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or continuous) in the treatment of THROMBOEMBOLISM,THROMBOEMBOLISM,HEPARIN
788860284,9/15/2015 20:54:16,1739002327,9/15/2015 20:53:44,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],MISOPROSTOL GASTRIC ULCER,treat,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 20:56:18,1739004302,9/15/2015 20:53:47,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",two doses MISOPROSTOL cimetidine duodenal GASTRIC ULCER studies.,there is relation,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 20:57:08,1739005121,9/15/2015 20:55:49,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],comparisons,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 20:58:23,1739006567,9/15/2015 20:55:47,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],doses of,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:04:47,1739014116,9/15/2015 21:04:28,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],and cimetidine,n/a,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:05:40,1739015115,9/15/2015 21:03:47,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],studies.,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:12:02,1739021092,9/15/2015 21:10:51,false,instagc,1,20312760,GBR,O1,Dukinfield,2.96.59.31,[TREATS],[TREATS],doses,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:13:19,1739022478,9/15/2015 21:11:46,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],GASTRIC ULCER,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:24:01,1739030522,9/15/2015 21:21:44,false,instagc,1,21350475,USA,SC,Easley,23.120.80.226,[TREATS],[TREATS],two doses,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:27:55,1739032746,9/15/2015 21:27:24,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],studies.,n/a,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:28:40,1739033208,9/15/2015 21:27:38,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],double blind comparisons,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:30:40,1739034428,9/15/2015 21:29:43,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],doses,N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:32:10,1739035261,9/15/2015 21:31:27,false,prodege,1,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],misoprostol in two duodenal ulcer studies,N/a,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:33:04,1739035704,9/15/2015 21:32:30,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],clinical trials,n/a,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860284,9/15/2015 21:42:03,1739040450,9/15/2015 21:41:38,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[MANIFESTATION] [CAUSES] [TREATS] [NONE],"[TREATS]
[CAUSES]
[MANIFESTATION]
[NONE]",[PREVENTS],N/A,323,274,336,335,285,RO-may_prevent,820382-FS1,"Five large controlled multicenter multicountry clinical trials have been conducted with misoprostol, including double blind placebo controlled comparisons of misoprostol in two duodenal ulcer studies and one gastric ulcer study, and double blind comparisons of two doses of MISOPROSTOL and cimetidine in duodenal ulcer and GASTRIC ULCER studies.",GASTRIC ULCER,MISOPROSTOL
788860285,9/16/2015 01:35:07,1739124063,9/16/2015 01:34:55,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],combination,N/A,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 01:55:28,1739142441,9/16/2015 01:55:14,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],of,n/a,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 01:59:28,1739145607,9/16/2015 01:59:16,false,elite,1.0,30659677,USA,"","",162.252.172.126,[MANIFESTATION],[MANIFESTATION],combination,N/A,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:03:22,1739148735,9/16/2015 02:02:32,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[OTHER],[OTHER],Management,n/a,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:21:44,1739164416,9/16/2015 02:21:31,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CONTRAINDICATES],[CONTRAINDICATES],combination,N/A,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:45:03,1739185922,9/16/2015 02:44:23,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[SIDE_EFFECT] [ASSOCIATED_WITH] [CONTRAINDICATES] [NONE],"[CONTRAINDICATES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]",DVSD,VGERV GRTG,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:50:35,1739191402,9/16/2015 02:49:12,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],Hypertension,N/A,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:56:46,1739196907,9/16/2015 02:56:37,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:57:07,1739197233,9/16/2015 02:56:56,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],combination,N/A,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:57:50,1739197827,9/16/2015 02:57:10,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,prindolol manages hypertension,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 02:58:25,1739198262,9/16/2015 02:57:54,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 03:20:25,1739218060,9/16/2015 03:19:57,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HYPERTENSION,NONE,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 03:24:19,1739221943,9/16/2015 03:23:40,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[PART_OF],[PART_OF],in combination with,N/A,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 03:36:19,1739233181,9/16/2015 03:34:52,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[OTHER],[OTHER],Uses,N/A,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860285,9/16/2015 03:58:10,1739253276,9/16/2015 03:57:06,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],Blocking Agents,n/a,165,91,177,176,100,RO-may_treat,820020-FS1,"1 ,   2 ,   3 ,   4  Class:  beta Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  PRINDOLOL; Pindolol; Viskazide; Visken  Uses  Hypertension  Management of HYPERTENSION (alone or in combination with other classes of antihypertensive agents.",HYPERTENSION,PRINDOLOL
788860286,9/16/2015 03:08:01,1739207095,9/16/2015 03:07:43,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],therapy.,Treat,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 03:35:08,1739232050,9/16/2015 03:34:14,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SYMPTOM],[SYMPTOM],HEART FAILURE,NONE,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 03:39:17,1739235974,9/16/2015 03:37:51,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",It is concluded that should be added to,N/A,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 03:45:18,1739241719,9/16/2015 03:44:59,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],added standard therapy.,N/A,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 04:07:14,1739261428,9/16/2015 04:06:48,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],CONGESTIVE HEART FAILURE many cases DIGOXIN should be standard therapy.,N/A,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 04:12:17,1739266261,9/16/2015 04:11:31,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",should be added to,n/a,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 04:19:15,1739273009,9/16/2015 04:18:49,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[LOCATION] [SIDE_EFFECT] [OTHER] [NONE],"[LOCATION]
[SIDE_EFFECT]
[OTHER]
[NONE]",nothing,nothing,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 05:17:29,1739332493,9/16/2015 05:16:51,false,elite,1.0,29216801,USA,"","",172.164.36.118,[TREATS],[TREATS],added,N/A,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 05:17:40,1739332670,9/16/2015 05:17:22,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],should be added to standard therapy.,n/a,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 05:31:05,1739345673,9/16/2015 05:29:15,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",hemodynamics needed CONGESTIVE HEART FAILURE cases DIGOXIN should be added standard therapy.,n/a,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 05:31:29,1739346091,9/16/2015 05:29:45,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],DIGOXIN should be added to standard therapy.,N/A,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 05:58:03,1739376730,9/16/2015 05:57:33,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],standard therapy.,N/A,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 05:58:41,1739377299,9/16/2015 05:58:16,false,neodev,1,34429821,USA,CA,San Jose,50.118.172.120,[NONE],[NONE],[NONE],[NONE]  beacuse is correct,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 06:13:18,1739388783,9/16/2015 06:12:02,false,clixsense,1,31482589,NLD,11,Gouda,77.167.232.121,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",should be added to standard therapy.,n/a,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860286,9/16/2015 06:36:12,1739403244,9/16/2015 06:34:49,false,instagc,1,33467170,USA,WV,Martinsburg,76.106.109.7,[TREATS],[TREATS],should be added to standard therapy.,N/A,65,152,89,88,159,RO-may_prevent,820263-FS1,It is concluded that if improvement of hemodynamics is needed in CONGESTIVE HEART FAILURE this knowledge should be taken into account and in many cases DIGOXIN should be added to standard therapy.,CONGESTIVE HEART FAILURE,DIGOXIN
788860287,9/16/2015 01:21:07,1739115518,9/16/2015 01:20:07,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],used for,n/a,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 01:34:20,1739123512,9/16/2015 01:34:06,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used,N/A,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 01:50:48,1739139064,9/16/2015 01:48:54,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[CAUSES],[CAUSES],may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,N/A,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 01:54:35,1739141798,9/16/2015 01:54:23,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],used concomitantly,n/a,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 01:55:42,1739142687,9/16/2015 01:54:39,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used,N/A,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:01:38,1739147197,9/16/2015 02:01:08,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],are used,n/a,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:20:54,1739163622,9/16/2015 02:20:42,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],increase,N/A,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:43:18,1739184195,9/16/2015 02:42:52,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[NONE]",RVG,CSD RFGER,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:46:23,1739187135,9/16/2015 02:45:37,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],DIGOXIN used for CHF,treats,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:47:41,1739188459,9/16/2015 02:47:12,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],digoxin,N/A,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:52:28,1739193090,9/16/2015 02:51:49,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],increase,N/A,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:54:54,1739195189,9/16/2015 02:54:17,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,Digoxin is used for chf,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:55:29,1739195697,9/16/2015 02:54:54,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 02:56:17,1739196390,9/16/2015 02:55:26,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],Serum,Treat,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860287,9/16/2015 03:21:39,1739219159,9/16/2015 03:21:09,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],digoxin,NONE,128,93,131,130,100,RO-may_prevent,820385-FS1,a ]   Captopril Serum digoxin concentrations may increase by about 15 30% when captopril and DIGOXIN are used concomitantly for CHF,CHF,DIGOXIN
788860288,9/16/2015 03:06:03,1739205444,9/16/2015 03:05:46,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,Drug,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 03:11:57,1739210480,9/16/2015 03:11:25,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,clopidogrel is a treatment for myocardial inffarction,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 03:31:22,1739228287,9/16/2015 03:30:44,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MYOCARDIAL INFARCTION,NONE,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 03:35:18,1739232194,9/16/2015 03:34:46,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],in the treatment of,N/A,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 03:43:43,1739240199,9/16/2015 03:43:28,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],in the treatment,N/A,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 04:05:27,1739259739,9/16/2015 04:05:06,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],CLOPIDOGREL breakthrough treatment of MYOCARDIAL INFARCTION,N/A,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 04:08:01,1739262153,9/16/2015 04:07:28,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment of,n/a,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 04:17:47,1739271552,9/16/2015 04:17:37,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[NONE] [OTHER],"[OTHER]
[NONE]",none,none,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 04:29:44,1739283028,9/16/2015 04:29:34,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,[TREATS],[TREATS],MYOCARDIAL,It makes sense,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 04:33:54,1739287809,9/16/2015 04:32:39,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [TREATS],"[TREATS]
[NONE]",the treatment,N/A,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 04:54:28,1739309005,9/16/2015 04:53:27,false,neodev,1.0,33739744,USA,VA,Manassas,207.244.83.121,[CAUSES] [SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE] [OTHER],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[OTHER]
[NONE]",They are related because they are terms used in medicine,N/a,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 05:13:49,1739328825,9/16/2015 05:13:35,false,elite,1.0,29216801,USA,"","",172.164.36.118,[TREATS],[TREATS],treatment,N/A,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 05:16:19,1739331227,9/16/2015 05:16:03,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],in the treatment of,n/a,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 05:19:13,1739334092,9/16/2015 05:16:58,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[TREATS],[TREATS],CLOPIDOGREL publicized press as breakthrough in treatment MYOCARDIAL INFARCTION,n/a,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860288,9/16/2015 05:24:19,1739338700,9/16/2015 05:22:39,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,115,32,136,135,43,RO-may_prevent,820386-FS1,Recently the anti platelet drug CLOPIDOGREL has been publicized in the press as a breakthrough in the treatment of MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,CLOPIDOGREL
788860289,9/15/2015 22:26:28,1739058166,9/15/2015 22:26:04,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],control,n/a,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 22:41:09,1739063184,9/15/2015 22:40:29,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],NEDOCROMIL SODIUM led to greater ASTHMA symptom control,na,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 22:45:24,1739064464,9/15/2015 22:45:08,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[SIDE_EFFECT],[SIDE_EFFECT],led to greater,n/a,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 22:54:30,1739067728,9/15/2015 22:53:45,false,clixsense,1.0,6330007,AUS,"","",101.178.25.217,[TREATS],[TREATS],greater symptom control,n/a,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 22:56:21,1739068283,9/15/2015 22:55:55,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],symptom control,N/A,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 23:17:30,1739075243,9/15/2015 23:17:00,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[PREVENTS] [SYMPTOM],"[PREVENTS]
[SYMPTOM]",symptom control,n/a,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 23:36:03,1739080853,9/15/2015 23:34:24,false,elite,1.0,31722487,USA,UT,Providence,206.190.129.237,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",therefore led to greater,N/A,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 23:37:00,1739081148,9/15/2015 23:36:30,false,neodev,1.0,31294288,USA,UT,Providence,206.190.129.237,[MANIFESTATION] [CONTRAINDICATES],"[MANIFESTATION]
[CONTRAINDICATES]",led to greater,N/A,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/15/2015 23:41:36,1739082517,9/15/2015 23:41:17,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [MANIFESTATION] [IS_A] [LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [CONTRAINDICATES] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",good,nt with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuter,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/16/2015 00:07:10,1739089156,9/16/2015 00:06:14,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",symptom control,N/A,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/16/2015 00:21:02,1739092211,9/16/2015 00:20:48,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[CAUSES],[CAUSES],led to greater,N/A,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/16/2015 00:44:52,1739098033,9/16/2015 00:43:22,false,clixsense,1.0,22947672,GBR,H9,London,146.198.116.72,[TREATS] [OTHER],"[TREATS]
[OTHER]",treatment with NEDOCROMIL SODIUM led to greater ASTHMA symptom control,n/a,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/16/2015 00:47:47,1739098679,9/16/2015 00:47:09,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],Regular treatment,n/a,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/16/2015 00:49:28,1739099074,9/16/2015 00:48:02,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Regular treatment with NEDOCROMIL SODIUM led to greater ASTHMA symptom control,Treats,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860289,9/16/2015 00:54:46,1739100628,9/16/2015 00:52:02,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,66,23,72,71,40,RO-may_prevent,820265-FS1,Regular treatment with NEDOCROMIL SODIUM therefore led to greater ASTHMA symptom control and reduced bronchial responsiveness compared with regular treatment with albuterol.,ASTHMA,NEDOCROMIL SODIUM
788860290,9/15/2015 23:46:38,1739083735,9/15/2015 23:46:23,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[LOCATION] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[ASSOCIATED_WITH]
[OTHER]
[NONE]",bad,IMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the fi,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 00:12:35,1739090502,9/16/2015 00:12:03,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[SIDE_EFFECT] [TREATS],"[TREATS]
[SIDE_EFFECT]",was cost effective,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 00:59:25,1739102573,9/16/2015 00:58:58,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",was cost effective,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 01:03:43,1739104663,9/16/2015 01:02:12,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],effective in both gastric ulcer and,n/a,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 01:31:23,1739121546,9/16/2015 01:31:03,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SIDE_EFFECT],[SIDE_EFFECT],effective,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 01:32:35,1739122340,9/16/2015 01:31:38,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],CIMETIDINE was cost effective DUODENAL ULCER,"It was cost effective, but didn't say if it was effective in other ways",56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 01:34:07,1739123462,9/16/2015 01:33:35,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],CIMETIDINE was cost effective in DUODENAL ULCER,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 01:49:54,1739138398,9/16/2015 01:49:24,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],effective,n/a,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 01:51:02,1739139202,9/16/2015 01:50:44,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SIDE_EFFECT],[SIDE_EFFECT],effective,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 01:51:52,1739139826,9/16/2015 01:51:35,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],and,n/a,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 02:17:10,1739160255,9/16/2015 02:16:59,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SIDE_EFFECT],[SIDE_EFFECT],effective,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 02:37:19,1739178317,9/16/2015 02:36:48,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",GVHJ,SW DSED,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 02:39:11,1739180105,9/16/2015 02:36:25,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],effective,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 02:39:13,1739180128,9/16/2015 02:37:34,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[PREVENTS],[PREVENTS],CIMETIDINE,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860290,9/16/2015 02:44:36,1739185594,9/16/2015 02:43:51,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[TREATS],[TREATS],cost effective,N/A,56,0,70,69,10,RO-may_prevent,820145-FS1,CIMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the first 2 years after healing.,DUODENAL ULCER,CIMETIDINE
788860291,9/15/2015 21:06:10,1739015639,9/15/2015 21:05:47,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],LEVOTHYROXINE HYPOTHYROIDISM,cares,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:09:21,1739018068,9/15/2015 21:09:09,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment of,N/A,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:09:48,1739018582,9/15/2015 21:08:35,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:13:55,1739023224,9/15/2015 21:13:45,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treatment,n/a,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:18:40,1739027588,9/15/2015 21:18:14,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],LEVOTHYROXINE treatment HYPOTHYROIDISM,treatment,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:37:36,1739038119,9/15/2015 21:37:14,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:42:01,1739040440,9/15/2015 21:41:45,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",treatment of,n/a,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:43:10,1739041074,9/15/2015 21:42:55,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:51:23,1739045222,9/15/2015 21:50:56,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [TREATS] [LOCATION] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[TREATS]
[PREVENTS]
[LOCATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",[PREVENTS],N/A,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 21:53:11,1739046009,9/15/2015 21:52:29,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 22:21:48,1739056834,9/15/2015 22:21:34,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 22:24:37,1739057612,9/15/2015 22:24:24,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],LEVOTHYROXINE the treatment of HYPOTHYROIDISM,n/a,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 22:29:14,1739059118,9/15/2015 22:27:58,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 22:29:26,1739059162,9/15/2015 22:28:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],LEVOTHYROXINE is choice for treatment of HYPOTHYROIDISM,na,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860291,9/15/2015 22:41:31,1739063259,9/15/2015 22:41:05,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],treatment,n/a,76,0,90,89,13,RO-may_prevent,820147-FS1,LEVOTHYROXINE is the overwhelming choice of clinicians for the treatment of HYPOTHYROIDISM and for the suppression of goitre and thyroid nodules in selected cases.,HYPOTHYROIDISM,LEVOTHYROXINE
788860292,9/15/2015 21:02:51,1739011953,9/15/2015 21:02:12,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],DUODENAL ULCERS,cry,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:05:44,1739015181,9/15/2015 21:05:28,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treated,N/A,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:06:33,1739016077,9/15/2015 21:06:21,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treated with,N/A,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:12:20,1739021362,9/15/2015 21:12:05,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treated,n/a,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:13:04,1739022133,9/15/2015 21:12:10,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",DUODENAL ULCERS treated RANITIDINE,treatment,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:19:42,1739028125,9/15/2015 21:19:31,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treated,N/A,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:30:53,1739034566,9/15/2015 21:30:20,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],were treated either with,N/A,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:39:48,1739039308,9/15/2015 21:39:29,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],treated with,n/a,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:41:24,1739040099,9/15/2015 21:41:07,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treated,n/a,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:48:16,1739043814,9/15/2015 21:47:50,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF] [SIDE_EFFECT] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[SIDE_EFFECT]
[PART_OF]
[NONE]",[PREVENTS],N/A,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 21:49:26,1739044364,9/15/2015 21:48:29,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treated,N/A,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 22:20:10,1739056232,9/15/2015 22:19:57,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],were treated,n/a,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 22:21:57,1739056876,9/15/2015 22:21:41,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],DUODENAL ULCERS were treated with RANITIDINE,n/a,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 22:23:31,1739057303,9/15/2015 22:23:04,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treated either with,N/A,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860292,9/15/2015 22:25:20,1739057832,9/15/2015 22:24:12,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],DUODENAL ULCERS treated with RANITIDINE,na,34,75,49,48,85,RO-may_prevent,820148-FS1,"For this purpose 30 patients with DUODENAL ULCERS were treated either with RANITIDINE alone (15) or together with bacampicillin (15), which was shown to be highly active in studies with ampicillin in vitro.",DUODENAL ULCERS,RANITIDINE
788860293,9/15/2015 21:03:32,1739012674,9/15/2015 21:02:53,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],AMINOGLYCOSIDE BACTERIAL INFECTIONS,treat,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:06:11,1739015650,9/15/2015 21:05:46,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:06:57,1739016319,9/15/2015 21:06:34,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment of,N/A,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:12:34,1739021524,9/15/2015 21:12:22,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treatment,n/a,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:14:03,1739023365,9/15/2015 21:13:05,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],treatment BACTERIAL INFECTIONS,treatment,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:20:07,1739028425,9/15/2015 21:19:43,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:32:53,1739035609,9/15/2015 21:30:58,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:40:07,1739039453,9/15/2015 21:39:49,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[TREATS],[TREATS],treatment,n/a,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:41:40,1739040252,9/15/2015 21:41:26,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:48:43,1739044056,9/15/2015 21:48:18,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [ASSOCIATED_WITH] [IS_A] [NONE],"[PREVENTS]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[PREVENTS],N/A,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 21:49:43,1739044474,9/15/2015 21:49:28,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 22:20:27,1739056328,9/15/2015 22:20:10,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],initial treatment,n/a,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 22:22:34,1739057055,9/15/2015 22:21:58,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],AMINOGLYCOSIDE is initial treatment of BACTERIAL INFECTIONS,n/a,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 22:24:36,1739057607,9/15/2015 22:23:32,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860293,9/15/2015 22:27:28,1739058448,9/15/2015 22:26:04,false,neodev,1,30749660,USA,NC,Wake Forest,71.70.155.5,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",AMINOGLYCOSIDE adequate for initial,n/a,173,107,193,192,121,RO-may_prevent,820303-FS1,A study of the susceptibility pattern of these organisms suggests that a combination of ampicillin with an AMINOGLYCOSIDE is adequate for initial treatment of these serious BACTERIAL INFECTIONS but the combination is not optimal for the treatment of Salmonella infections.,BACTERIAL INFECTIONS,AMINOGLYCOSIDE
788860294,9/15/2015 21:08:18,1739017342,9/15/2015 21:07:26,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],INTRA AMNIOTIC THYROXINE polyhydramnios.,treat,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:10:26,1739019418,9/15/2015 21:10:03,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],used to treat,N/A,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:10:51,1739019903,9/15/2015 21:10:28,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treat,N/A,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:14:46,1739024286,9/15/2015 21:14:17,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treat,n/a,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:20:28,1739028614,9/15/2015 21:19:40,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],INTRA AMNIOTIC THYROXINE to treat HYPOTHYROIDISM correct development polyhydramnios.,treatment,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:40:08,1739039457,9/15/2015 21:39:25,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[CONTRAINDICATES],[CONTRAINDICATES],should not be used to treat,N/A,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:42:50,1739040951,9/15/2015 21:42:37,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],treat the,n/a,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:43:57,1739041533,9/15/2015 21:43:33,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],should not be used to treat,n/a,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:52:35,1739045819,9/15/2015 21:51:53,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[SYMPTOM] [PREVENTS] [CONTRAINDICATES] [IS_A] [NONE],"[PREVENTS]
[SYMPTOM]
[CONTRAINDICATES]
[IS_A]
[NONE]",[PREVENTS],N/A,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 21:55:32,1739047013,9/15/2015 21:55:06,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CONTRAINDICATES],[CONTRAINDICATES],should not be used to treat,N/A,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 22:22:26,1739056994,9/15/2015 22:22:09,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CONTRAINDICATES],[CONTRAINDICATES],should not be used,n/a,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 22:25:41,1739057910,9/15/2015 22:25:01,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],INTRA AMNIOTIC THYROXINE should not be used to treat HYPOTHYROIDISM of,n/a,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 22:30:00,1739059373,9/15/2015 22:29:41,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],should not be used,N/A,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 22:32:31,1739060269,9/15/2015 22:30:37,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],INTRA AMNIOTIC THYROXINE should not be used to treat HYPOTHYROIDISM,na,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860294,9/15/2015 22:42:36,1739063566,9/15/2015 22:42:03,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],treat,n/a,71,14,85,84,38,RO-may_prevent,820149-FS1,We argue that INTRA AMNIOTIC THYROXINE should not be used to treat the HYPOTHYROIDISM but only to correct the development of polyhydramnios.,HYPOTHYROIDISM,INTRA AMNIOTIC THYROXINE
788860295,9/15/2015 23:57:40,1739086916,9/15/2015 23:56:49,false,neodev,1.0,33228343,USA,"","",38.95.108.244,[LOCATION] [CONTRAINDICATES] [IS_A] [PART_OF] [NONE],"[LOCATION]
[CONTRAINDICATES]
[IS_A]
[PART_OF]
[NONE]",e not expected to have a domain knowledge in the topic of the sentence. It doesn't matter if you don't know what the highlighted words mean. It is important to understand what the diff,e not expected to have a domain knowledge in the topic of the sentence. It doesn't matter if you don't know what the highlighted words mean. It is important to understand what the diff,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 00:22:58,1739092752,9/16/2015 00:21:36,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",indicating that,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 01:08:34,1739107523,9/16/2015 01:08:11,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",positive for,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 01:20:05,1739114905,9/16/2015 01:19:25,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[PREVENTS],[PREVENTS],were positive for,n/a,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 01:34:04,1739123417,9/16/2015 01:33:51,false,elite,1,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],indicating,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 01:48:52,1739137597,9/16/2015 01:47:37,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 01:54:22,1739141681,9/16/2015 01:54:11,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],indicating,n/a,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 01:54:37,1739141857,9/16/2015 01:54:23,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],indicating,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 02:01:07,1739146782,9/16/2015 02:00:43,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[OTHER],[OTHER],target,n/a,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 02:20:41,1739163444,9/16/2015 02:20:26,false,elite,1,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],indicating,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 02:42:50,1739183745,9/16/2015 02:42:19,false,neodev,1,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[NONE]",HBHJB,RDRTED KJNMIJNM,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 02:45:36,1739186472,9/16/2015 02:44:44,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive for HBSAG indicating HEPATITIS B INFECTION in the target group,associated with,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 02:47:10,1739187986,9/16/2015 02:46:15,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],INFECTION,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 02:51:47,1739192420,9/16/2015 02:51:35,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],indicating,N/A,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860295,9/16/2015 02:55:25,1739195597,9/16/2015 02:54:17,false,elite,1,34356654,USA,DE,"",108.59.11.227,[OTHER],[OTHER],indicating,Other,69,47,91,89,52,RO-may_prevent,820307-FS1,"Of the 2,585 men, 24 (0.93%) were positive for HBSAG indicating that HEPATITIS B INFECTION in the target group was below the intermediate endemicity.",HEPATITIS B INFECTION,HBSAG
788860296,9/16/2015 01:36:04,1739124796,9/16/2015 01:35:50,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 01:57:00,1739143750,9/16/2015 01:56:38,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],and,n/a,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 02:02:00,1739147428,9/16/2015 02:01:28,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 02:05:51,1739150879,9/16/2015 02:05:06,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],treatment,n/a,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 02:22:52,1739165428,9/16/2015 02:22:40,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 02:47:14,1739188010,9/16/2015 02:46:47,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[NONE]",GHJGB,XHXF JGBHB,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 02:54:08,1739194502,9/16/2015 02:53:13,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HBSAG,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 02:58:39,1739198480,9/16/2015 02:58:30,false,neodev,1,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 02:58:45,1739198601,9/16/2015 02:58:27,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 03:01:34,1739201065,9/16/2015 02:59:29,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 03:02:34,1739201950,9/16/2015 03:01:18,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive for SERUM HEPATITIS B VIRUS DNA and HBSAG,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 03:23:01,1739220593,9/16/2015 03:22:08,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],SERUM HEPATITIS,NONE,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 03:27:37,1739224885,9/16/2015 03:26:46,false,points4rewards,1,28703583,USA,"","",184.53.32.159,[SYMPTOM],[SYMPTOM],evidence of active liver,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 03:39:08,1739235815,9/16/2015 03:38:35,false,clixsense,1,21665495,CAN,"","",24.105.69.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive for and,N/A,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860296,9/16/2015 03:59:35,1739254573,9/16/2015 03:58:55,false,neodev,1,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment were,n/a,300,332,315,326,337,RO-may_prevent,820151-FS1,"We assessed the safety and efficacy of thymosin fraction 5 and thymosin alpha 1 in a prospective, placebo controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for SERUM HEPATITIS B VIRUS DNA and HBSAG",SERUM HEPATITIS B VIRUS DNA,HBSAG
788860297,9/15/2015 22:27:16,1739058407,9/15/2015 22:27:03,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,[PREVENTS],[PREVENTS],preventing,n/a,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/15/2015 22:46:03,1739064705,9/15/2015 22:45:51,false,clixsense,1,28457001,CAN,ON,North Bay,24.204.202.220,[PREVENTS],[PREVENTS],preventing,n/a,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/15/2015 22:57:39,1739068652,9/15/2015 22:57:01,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[NONE],[NONE],N/A,not effective,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/15/2015 22:59:07,1739069091,9/15/2015 22:57:30,false,clixsense,1,6330007,AUS,"","",101.178.25.217,[PREVENTS],[PREVENTS],effective in preventing,n/a,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/15/2015 23:39:26,1739081929,9/15/2015 23:38:34,false,neodev,1,31294288,USA,UT,Providence,206.190.129.237,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",effective in preventing,N/A,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/15/2015 23:42:30,1739082753,9/15/2015 23:42:11,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [CONTRAINDICATES] [SIDE_EFFECT] [OTHER] [NONE],"[PREVENTS]
[CONTRAINDICATES]
[SIDE_EFFECT]
[OTHER]
[NONE]",bad,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/15/2015 23:54:53,1739086060,9/15/2015 23:54:09,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",effective in preventing,N/A,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 00:22:05,1739092485,9/16/2015 00:21:21,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,[NONE],[NONE],N/A,The sentence states that there is no reviews that fluorine prevents dental caries.,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 00:47:19,1739098601,9/16/2015 00:46:57,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[PREVENTS],[PREVENTS],in preventing,N/A,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 00:50:02,1739099195,9/16/2015 00:47:37,false,clixsense,1,22947672,GBR,H9,London,146.198.116.72,[NONE],[NONE],n/a,not related,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 00:50:32,1739099388,9/16/2015 00:49:35,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[PREVENTS],[PREVENTS],effective in preventing,n/a,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 00:56:10,1739101039,9/16/2015 00:54:47,false,clixsense,1,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 01:14:44,1739111878,9/16/2015 01:12:45,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],N/A,It says that flouride has not been effective,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 01:16:31,1739112845,9/16/2015 01:15:20,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[PREVENTS],[PREVENTS],FLUORIDE to be effective in preventing DENTAL CARIES,FLUORIDE to be effective in preventing DENTAL CARIES,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860297,9/16/2015 01:21:59,1739115925,9/16/2015 01:21:17,false,neodev,1,11291592,USA,MI,Taylor,99.170.106.105,[NONE],[NONE],non,n/a,81,42,94,93,50,RO-may_prevent,820275-FS1,"To date, no systematic reviews have found FLUORIDE to be effective in preventing DENTAL CARIES in adults.",DENTAL CARIES,FLUORIDE
788860298,9/15/2015 21:02:10,1739011114,9/15/2015 21:01:41,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],GASTRIC ULCER CIMETIDINE,is,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:05:25,1739014853,9/15/2015 21:05:07,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:06:20,1739015834,9/15/2015 21:06:03,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment of,N/A,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:12:01,1739021065,9/15/2015 21:11:40,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],comparison with,n/a,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:12:05,1739021144,9/15/2015 21:11:37,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],therapeutic treatment GASTRIC ULCER CIMETIDINE,treatment,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:19:29,1739028005,9/15/2015 21:19:17,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:30:16,1739034201,9/15/2015 21:29:28,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:39:27,1739039165,9/15/2015 21:39:13,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],comparison,n/a,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:41:04,1739039974,9/15/2015 21:40:31,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:47:49,1739043606,9/15/2015 21:47:20,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[TREATS] [LOCATION] [SIDE_EFFECT] [OTHER] [NONE],"[TREATS]
[LOCATION]
[SIDE_EFFECT]
[OTHER]
[NONE]",[PREVENTS],N/A,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 21:48:28,1739043954,9/15/2015 21:48:05,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],with,N/A,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 22:19:55,1739056139,9/15/2015 22:19:39,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],comparison,n/a,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 22:21:40,1739056788,9/15/2015 22:21:27,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],treatment of GASTRIC ULCER with CIMETIDINE,n/a,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 22:23:04,1739057187,9/15/2015 22:22:00,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],in comparison with,N/A,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860298,9/15/2015 22:24:11,1739057516,9/15/2015 22:23:27,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GASTRIC ULCER in comparison with CIMETIDINE,na,58,91,71,70,101,RO-may_prevent,820276-FS1,This underlines its therapeutic value in the treatment of GASTRIC ULCER in comparison with CIMETIDINE or carbenoxolone.,GASTRIC ULCER,CIMETIDINE
788860299,9/16/2015 01:21:49,1739115851,9/16/2015 01:21:09,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],TREATMENT of serious,n/a,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 01:34:33,1739123645,9/16/2015 01:34:22,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],serious,N/A,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 01:54:51,1739142056,9/16/2015 01:54:36,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[PART_OF],[PART_OF],of serious,n/a,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 01:56:57,1739143707,9/16/2015 01:55:44,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],TREATMENT,N/A,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:01:55,1739147359,9/16/2015 02:01:39,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],TREATMENT,n/a,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:21:15,1739163975,9/16/2015 02:20:55,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],serious,N/A,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:43:47,1739184671,9/16/2015 02:43:21,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[ASSOCIATED_WITH] [LOCATION] [SYMPTOM] [NONE],"[LOCATION]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]",DCD,VSD WEFEW,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:47:05,1739187844,9/16/2015 02:46:24,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION,treats,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:48:29,1739189338,9/16/2015 02:47:43,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[TREATS],[TREATS],GANCICLOVIR TREATMENT,N/A,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:53:20,1739193829,9/16/2015 02:52:29,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],TREATMENT,N/A,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:55:37,1739195949,9/16/2015 02:54:55,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,The infection is treated by the treatment,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:56:11,1739196367,9/16/2015 02:55:35,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 02:57:33,1739197574,9/16/2015 02:56:22,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 03:19:25,1739217198,9/16/2015 03:18:35,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],TREATMENT,NONE,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860299,9/16/2015 03:22:54,1739220513,9/16/2015 03:21:43,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],TREATMENT of,N/A,71,38,96,95,59,RO-may_prevent,820156-FS1,"Keay S, Petersen E, Icenogle T et al. GANCICLOVIR TREATMENT of serious CYTOMEGALOVIRUS INFECTION in heart and heart lung transplant recipients.",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR TREATMENT
788860300,9/15/2015 21:05:45,1739015195,9/15/2015 21:05:12,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],SURFACE ANTIGEN (HBSAG) HEPATITIS B,prevent,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:08:32,1739017549,9/15/2015 21:07:52,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"positive,",N/A,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:09:07,1739017947,9/15/2015 21:08:43,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"was positive,",N/A,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:13:43,1739022943,9/15/2015 21:13:32,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],"positive,",n/a,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:18:13,1739027287,9/15/2015 21:16:52,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[ASSOCIATED_WITH] [SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]
[ASSOCIATED_WITH]",serum SURFACE ANTIGEN unlikely serum HEPATITIS B negative stain liver tissue.,there is relation,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:21:01,1739028892,9/15/2015 21:20:30,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:37:09,1739037871,9/15/2015 21:35:56,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,Their relation can't be highlighted.,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:41:44,1739040284,9/15/2015 21:41:12,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],serum,n/a,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:42:54,1739040962,9/15/2015 21:42:31,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],reactivation,n/a,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:50:55,1739045052,9/15/2015 21:50:25,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[LOCATION] [PREVENTS] [TREATS] [PART_OF] [NONE],"[TREATS]
[PREVENTS]
[LOCATION]
[PART_OF]
[NONE]",[PREVENTS],N/A,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 21:52:28,1739045758,9/15/2015 21:51:22,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],serum,N/A,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 22:21:33,1739056717,9/15/2015 22:21:07,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"was positive,",n/a,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 22:24:22,1739057559,9/15/2015 22:23:45,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[MANIFESTATION],[MANIFESTATION],B SURFACE ANTIGEN (HBSAG) hepatitis B,n/a,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 22:27:57,1739058601,9/15/2015 22:26:40,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[LOCATION],[LOCATION],SURFACE,N/A,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860300,9/15/2015 22:28:46,1739058967,9/15/2015 22:28:02,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],B SURFACE ANTIGEN (HBSAG) HEPATITIS B,na,139,22,91,149,45,RO-may_prevent,820313-FS1,"The serum hepatitis B SURFACE ANTIGEN (HBSAG) was positive, but reactivation of hepatitis B was unlikely in view of the absence of a serum HEPATITIS B e antigen (HBeAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) and negative stain for HBsAg and hepatitis B core antigen (HBcAg) in the liver tissue.",HEPATITIS B,SURFACE ANTIGEN (HBSAG)
788860301,9/15/2015 23:43:46,1739083032,9/15/2015 23:43:31,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[CONTRAINDICATES] [ASSOCIATED_WITH] [SYMPTOM] [NONE],"[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",bad,ubcutaneous calcium heparin can substitute the intravenous form of HEPARIN (either bolus or,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 00:04:34,1739088424,9/16/2015 00:03:45,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[CONTRAINDICATES]","prevalence of drug resistance,",N/A,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 00:24:18,1739093023,9/16/2015 00:23:31,false,neodev,1.0,31294288,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"the prevalence of drug resistance,",N/A,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 00:50:24,1739099357,9/16/2015 00:49:28,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",drug regimen containing,N/A,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 00:54:37,1739100582,9/16/2015 00:53:32,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],drug regimen containing,n/a,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:03:02,1739104310,9/16/2015 01:01:10,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:21:02,1739115476,9/16/2015 01:19:57,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],"CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS","CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:21:36,1739115719,9/16/2015 01:19:01,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],drug regimen containing CHEMOTHERAPY PYRAZINAMIDE TUBERCULOSIS,treats,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:23:06,1739116628,9/16/2015 01:22:58,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,[NONE],[NONE],none,n/a,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:26:28,1739118755,9/16/2015 01:26:19,false,neodev,1,33739202,USA,MS,Madison,75.65.195.220,[TREATS] [PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[NONE]",omplicaciones en el Parkinson enfermedad Lisuride de levodopa inducida complicaciones en el Parkinson enfermedad Lisuride frente bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad No farmacológicas terapias para la disfagia en el Parkinson enfermedad La pergolida para levodopa INDUCIDA COMPLICACIONES en de Parkinson enfermedad La pergolida en comparación con la bromocriptina para levodopa inducida motor complicaciones en DE PARKINSON ENFERMEDAD El pramipexol de levodopa inducida complicaciones en el Parkinson enfermedad El pramipexol en comparación con la bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol de levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol frente bromocriptina para levodopa inducida complicaciones en el Parkinson.,omplicaciones en el Parkinson enfermedad Lisuride de levodopa inducida complicaciones en el Parkinson enfermedad Lisuride frente bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad No farmacológicas terapias para la disfagia en el Parkinson enfermedad La pergolida para levodopa INDUCIDA COMPLICACIONES en de Parkinson enfermedad La pergolida en comparación con la bromocriptina para levodopa inducida motor complicaciones en DE PARKINSON ENFERMEDAD El pramipexol de levodopa inducida complicaciones en el Parkinson enfermedad El pramipexol en comparación con la bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol de levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol frente bromocriptina para levodopa inducida complicaciones en el Parkinson.,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:27:23,1739119318,9/16/2015 01:26:18,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHEMOTHERAPY PYRAZINAMIDE TUBERCULOSIS,nnnnn/a,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:29:03,1739120173,9/16/2015 01:28:51,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,N/A,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:43:03,1739133128,9/16/2015 01:42:36,false,elite,1,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,N/A,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:44:07,1739133948,9/16/2015 01:42:45,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],Two drug,n/a,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860301,9/16/2015 01:47:47,1739136794,9/16/2015 01:47:28,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,N/A,359,281,371,370,306,RO-may_prevent,820317-FS1,"Two drug regimen of chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis is the one of the standard methods of treatment for active pulmonary tuberculosis in Japan since 1996, while ATS/CDC and WHO/IUATLD recommended the three drug or four drug regimen containing CHEMOTHERAPY PYRAZINAMIDE unless the prevalence of drug resistance, among new TUBERCULOSIS cases is low.",TUBERCULOSIS,CHEMOTHERAPY PYRAZINAMIDE
788860302,9/15/2015 23:45:00,1739083297,9/15/2015 23:44:42,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [MANIFESTATION] [LOCATION] [CAUSES] [NONE],"[PREVENTS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[NONE]",bad,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 00:08:02,1739089385,9/16/2015 00:07:26,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and Granisetron,N/A,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 00:55:43,1739100939,9/16/2015 00:53:48,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[NONE],[NONE],N/A,seem to be different illnesses,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 00:58:09,1739101820,9/16/2015 00:57:33,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],Study Group.,n/a,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 01:25:34,1739118160,9/16/2015 01:24:42,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PART_OF],[PART_OF],ONDANSETRON and Granisetron EMESIS Study Group.,part of,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 01:27:47,1739119619,9/16/2015 01:26:54,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[OTHER],[OTHER],ONDANSETRON and Granisetron EMESIS Study Group.,ONDANSETRON and Granisetron EMESIS Study Group.,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 01:30:00,1739120784,9/16/2015 01:29:48,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 01:44:24,1739134083,9/16/2015 01:44:05,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 01:46:48,1739135943,9/16/2015 01:45:48,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[PART_OF],[PART_OF],ONDANSETRON Granisetron EMESIS,n/a,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 01:48:52,1739137595,9/16/2015 01:48:34,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 01:50:21,1739138723,9/16/2015 01:50:07,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],and,n/a,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 02:15:57,1739159072,9/16/2015 02:15:44,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 02:33:20,1739174705,9/16/2015 02:31:31,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[OTHER],[OTHER],and,N/A,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 02:33:40,1739174963,9/16/2015 02:32:16,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[CAUSES],[CAUSES],ONDANSETRON,N/A,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860302,9/16/2015 02:34:13,1739175604,9/16/2015 02:33:38,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[LOCATION] [MANIFESTATION] [NONE],"[LOCATION]
[MANIFESTATION]
[NONE]",yjuh,gomu gomu,70,42,76,75,53,RO-may_prevent,820319-FS1,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",EMESIS,ONDANSETRON
788860303,9/15/2015 22:24:23,1739057558,9/15/2015 22:24:11,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 22:27:54,1739058594,9/15/2015 22:27:36,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",POSTMENOPAUSAL prevention treatment RISEDRONATE osteoporosis.,n/a,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 22:36:07,1739061531,9/15/2015 22:35:11,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[PREVENTS],[PREVENTS],prevention of,N/A,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 22:39:17,1739062643,9/15/2015 22:38:45,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],treatment of POSTMENOPAUSAL OSTEOPOROSIS RISEDRONATE,na,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 22:44:33,1739064137,9/15/2015 22:44:21,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",prevention treatment,n/a,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 22:49:00,1739065525,9/15/2015 22:47:43,false,prodege,1.0,34294822,USA,TX,Allen,99.7.230.126,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",prevention treatment,N/A,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 22:50:32,1739066004,9/15/2015 22:49:19,false,clixsense,1.0,6330007,AUS,"","",101.178.25.217,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",treatment of for prevention,n/a,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 22:54:15,1739067596,9/15/2015 22:53:34,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],treatment,N/A,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 23:15:17,1739074652,9/15/2015 23:14:52,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",prevention and treatment,n/a,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 23:31:41,1739079636,9/15/2015 23:31:08,false,elite,1.0,31722487,USA,UT,Providence,206.190.129.237,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",for prevention and treatment,N/A,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 23:34:45,1739080536,9/15/2015 23:33:51,false,neodev,1.0,31294288,USA,UT,Providence,206.190.129.237,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",prevention and treatment,N/A,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/15/2015 23:39:43,1739081995,9/15/2015 23:39:02,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[NONE] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [CAUSES] [MANIFESTATION] [ASSOCIATED_WITH] [IS_A] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",waste,"are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment.",127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/16/2015 00:03:10,1739088066,9/16/2015 00:01:15,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[NONE],[NONE],N/A,"one term is an illness and the other is a method of prevention of another illness, therefore unrelated.",127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/16/2015 00:19:39,1739091948,9/16/2015 00:19:24,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],for treatment treatment,N/A,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860303,9/16/2015 00:41:52,1739097128,9/16/2015 00:40:41,false,clixsense,1.0,22947672,GBR,H9,London,146.198.116.72,[TREATS],[TREATS],Alendronate and risedronate for treatment of POSTMENOPAUSAL OSTEOPOROSIS,n/a,127,219,154,153,230,RO-may_prevent,820281-FS1,"Alendronate and risedronate are approved by the FDA for prevention of bone loss in recently menopausal women, for treatment of POSTMENOPAUSAL OSTEOPOROSIS and for prevention (risedronate) and treatment (alendronate and RISEDRONATE of glucocorticoid induced osteoporosis.",POSTMENOPAUSAL OSTEOPOROSIS,RISEDRONATE
788860304,9/15/2015 23:47:49,1739084037,9/15/2015 23:47:35,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [SYMPTOM] [ASSOCIATED_WITH] [CONTRAINDICATES] [NONE],"[PREVENTS]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",kers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,kers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 00:16:16,1739091320,9/16/2015 00:15:34,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the incidence of new definite,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 01:03:45,1739104675,9/16/2015 01:02:32,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[CAUSES],[CAUSES],incidence of,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 01:15:13,1739112172,9/16/2015 01:12:55,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],new definite,n/a,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 01:32:35,1739122361,9/16/2015 01:32:21,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],incidence,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 01:40:15,1739130920,9/16/2015 01:38:53,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[MANIFESTATION],[MANIFESTATION],workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS,workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 01:52:23,1739140173,9/16/2015 01:51:57,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],incidence,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 01:52:47,1739140390,9/16/2015 01:52:36,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],definite,n/a,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 01:56:21,1739143218,9/16/2015 01:56:06,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[PART_OF],[PART_OF],versus,n/a,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 02:16:46,1739159905,9/16/2015 02:15:34,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],HEPATITIS B incidence new definite HEPATITIS B INFECTIONS,manifestations,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 02:18:16,1739161238,9/16/2015 02:18:02,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],incidence,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 02:39:32,1739180491,9/16/2015 02:39:05,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[SIDE_EFFECT] [CONTRAINDICATES] [MANIFESTATION] [NONE],"[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",GVHV,HB HBH,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 02:42:15,1739183145,9/16/2015 02:41:40,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[PART_OF],[PART_OF],HEPATITIS B,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 02:48:28,1739189271,9/16/2015 02:48:04,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],incidence,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860304,9/16/2015 02:53:39,1739194158,9/16/2015 02:52:40,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[IS_A],[IS_A],new definite,N/A,78,36,101,99,47,RO-may_prevent,820161-FS1,Among health workers susceptible to HEPATITIS B the incidence of new definite HEPATITIS B INFECTIONS was 1.0% per year in 362 health workers (804 person years of follow up observation) with frequent blood contact versus 0% per year in 258 health workers (534 person years of observation) with limited blood contact (p = 0.017.,HEPATITIS B INFECTIONS,HEPATITIS B
788860305,9/15/2015 23:44:21,1739083128,9/15/2015 23:44:05,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [SYMPTOM] [CAUSES] [LOCATION] [CONTRAINDICATES] [SIDE_EFFECT] [PART_OF] [NONE],"[PREVENTS]
[CAUSES]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[PART_OF]
[NONE]",bad,ees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 00:06:15,1739088825,9/16/2015 00:05:39,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",should avoid the use of,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 00:53:06,1739100246,9/16/2015 00:51:56,false,neodev,1.0,31294288,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",should avoid the use,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 00:53:18,1739100263,9/16/2015 00:52:18,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[CONTRAINDICATES],[CONTRAINDICATES],should avoid,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 00:56:37,1739101193,9/16/2015 00:56:01,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[CONTRAINDICATES],[CONTRAINDICATES],avoid the use of,n/a,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:07:33,1739106874,9/16/2015 01:07:24,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],back pain,back pain,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:23:31,1739116890,9/16/2015 01:22:39,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],pregnant lactating women with MALARIA should avoid CHLOROQUINE may cause spontaneous abortion dry up breast milk.,contraindicates,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:24:27,1739117402,9/16/2015 01:23:15,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[PREVENTS],[PREVENTS],pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause spontaneous abortion,pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:29:32,1739120457,9/16/2015 01:29:20,false,elite,1.0,30659615,USA,"","",162.250.145.234,[MANIFESTATION],[MANIFESTATION],avoid,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:43:48,1739133716,9/16/2015 01:43:32,false,elite,1.0,30659754,USA,"","",162.250.145.204,[OTHER],[OTHER],avoid,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:45:23,1739134865,9/16/2015 01:44:51,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[CAUSES],[CAUSES],spontaneous abortion dry up breast milk.,n/a,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:48:18,1739137146,9/16/2015 01:48:04,false,elite,1.0,30659677,USA,"","",162.252.172.126,[OTHER],[OTHER],avoid,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 01:49:46,1739138298,9/16/2015 01:49:29,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[SIDE_EFFECT],[SIDE_EFFECT],avoid,n/a,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 02:15:30,1739158670,9/16/2015 02:15:17,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[OTHER],[OTHER],avoid,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860305,9/16/2015 02:31:03,1739172667,9/16/2015 02:30:39,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[OTHER],[OTHER],avoid,N/A,86,118,93,92,129,RO-may_prevent,820282-FS1,Nearly two thirds of the interviewees believed that pregnant and lactating women with MALARIA should avoid the use of CHLOROQUINE because it may cause a spontaneous abortion or dry up breast milk.,MALARIA,CHLOROQUINE
788860306,9/15/2015 22:26:03,1739057990,9/15/2015 22:24:46,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],did not exist.,n/a,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 22:40:29,1739063035,9/15/2015 22:39:59,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],DENTAL CARIES and FLUORIDE CONCENTRATION inverse relationship did not exist.,na,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 22:45:08,1739064330,9/15/2015 22:44:55,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[NONE],[NONE],n/a,n/a,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 22:51:29,1739066246,9/15/2015 22:49:53,false,prodege,1.0,34294822,USA,TX,Allen,99.7.230.126,[NONE],[NONE],N/A,The statement says the given relationship actually does not exist.,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 22:53:44,1739067337,9/15/2015 22:52:04,false,clixsense,1.0,6330007,AUS,"","",101.178.25.217,[NONE],[NONE],n/a,according to the comment no relationship existed,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 22:55:54,1739068189,9/15/2015 22:54:56,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[NONE],[NONE],N/A,it says did not exist,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 23:17:00,1739075068,9/15/2015 23:16:03,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[CONTRAINDICATES],[CONTRAINDICATES],commonly accepted inverse relationship did not exist.,n/a,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 23:34:13,1739080361,9/15/2015 23:32:59,false,elite,1.0,31722487,USA,UT,Providence,206.190.129.237,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",relationship between,N/A,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 23:36:24,1739080976,9/15/2015 23:35:34,false,neodev,1.0,31294288,USA,UT,Providence,206.190.129.237,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",the relationship between,N/A,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/15/2015 23:41:15,1739082454,9/15/2015 23:40:27,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [CAUSES] [LOCATION] [SIDE_EFFECT] [CONTRAINDICATES] [SYMPTOM] [NONE],"[PREVENTS]
[CAUSES]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",good,sis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/16/2015 00:06:13,1739088778,9/16/2015 00:04:40,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",inverse relationship,N/A,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/16/2015 00:20:48,1739092118,9/16/2015 00:20:18,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[NONE],[NONE],N/A,The sentence states that there is no relation,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/16/2015 00:43:22,1739097641,9/16/2015 00:42:36,false,clixsense,1.0,22947672,GBR,H9,London,146.198.116.72,[LOCATION],[LOCATION],relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION,n/a,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/16/2015 00:47:08,1739098529,9/16/2015 00:45:01,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[PREVENTS],[PREVENTS],relationship between,n/a,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860306,9/16/2015 00:48:02,1739098747,9/16/2015 00:46:36,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],N/A,The sentence says that it was suggested that there was no relation between the terms.,74,107,87,86,129,RO-may_prevent,820162-FS1,A recent analysis of data from earlier papers on the relationship between DENTAL CARIES and drinking water FLUORIDE CONCENTRATION suggested that the commonly accepted inverse relationship did not exist.,DENTAL CARIES,FLUORIDE CONCENTRATION
788860307,9/15/2015 23:45:22,1739083415,9/15/2015 23:45:03,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [SIDE_EFFECT] [SYMPTOM] [CAUSES] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",bad,"Ruff P, Paska W, Goedhals L et al for the ONDANSETRON and Granisetron EMESIS Study Group.",117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 00:09:05,1739089607,9/16/2015 00:08:14,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",were given daily doses,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 00:56:27,1739101138,9/16/2015 00:55:45,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",given daily doses,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 00:58:55,1739102224,9/16/2015 00:58:09,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],were given daily doses,n/a,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 01:27:19,1739119292,9/16/2015 01:25:36,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],have been studied PLASMODIUM VIVAX MALARIA given daily doses PRIMAQUINE,were studied but didn't really tell of any results,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 01:30:16,1739120932,9/16/2015 01:30:03,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],given,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 01:30:43,1739121168,9/16/2015 01:27:49,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],PLASMODIUM VIVAX MALARIA who were given daily doses PRIMAQUINE following full course of chloroquine.,"PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 01:44:43,1739134424,9/16/2015 01:44:26,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],given,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 01:47:17,1739136308,9/16/2015 01:46:49,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],course,n/a,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 01:49:09,1739137754,9/16/2015 01:48:54,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],given,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 01:50:43,1739139012,9/16/2015 01:50:23,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[CAUSES],[CAUSES],following,n/a,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 02:16:13,1739159414,9/16/2015 02:15:59,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],doses,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 02:33:50,1739175119,9/16/2015 02:33:22,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],given,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 02:34:26,1739175823,9/16/2015 02:33:42,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[SYMPTOM],[SYMPTOM],PRIMAQUINE,N/A,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860307,9/16/2015 02:35:00,1739176276,9/16/2015 02:34:16,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[NONE]",huead,XD XD,117,181,141,140,191,RO-may_prevent,820164-FS1,"The pharmacokinetics of primaquine have been studied in 13 G6PD normal and 13 G6PD deficient Thai male patients with PLASMODIUM VIVAX MALARIA who were given daily doses of 15 mg of PRIMAQUINE over 14 d, following a full course of chloroquine.",PLASMODIUM VIVAX MALARIA,PRIMAQUINE
788860308,9/15/2015 20:58:47,1739007002,9/15/2015 20:58:17,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],AMPHOTERICIN B MYCOSES; aspergillus infections.,cares,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:02:17,1739011298,9/15/2015 21:01:55,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:02:50,1739011930,9/15/2015 21:02:33,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment for,N/A,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:04:08,1739013330,9/15/2015 21:02:52,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[OTHER],[OTHER],drug used empiric treatment candida aspergillus infections.,treatment for other infection,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:08:59,1739017855,9/15/2015 21:08:44,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],longer used exclusively,n/a,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:16:56,1739026239,9/15/2015 21:16:40,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:17:38,1739026894,9/15/2015 21:16:44,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [OTHER],"[TREATS]
[OTHER]",is no longer used exclusively for,N/A,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:36:47,1739037697,9/15/2015 21:36:20,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[TREATS],[TREATS],used,n/a,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:37:26,1739038006,9/15/2015 21:36:50,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],used,n/a,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:42:56,1739040965,9/15/2015 21:42:05,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 21:44:26,1739041798,9/15/2015 21:44:01,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[CAUSES] [IS_A] [ASSOCIATED_WITH] [NONE],"[CAUSES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[PREVENTS],N/A,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 22:14:04,1739054039,9/15/2015 22:13:49,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],AMPHOTERICIN B used exclusively for MYCOSES;,n/a,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 22:16:20,1739054837,9/15/2015 22:15:41,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],no longer used,N/A,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 22:17:17,1739055186,9/15/2015 22:16:34,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],no longer used exclusively,n/a,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860308,9/15/2015 22:18:05,1739055513,9/15/2015 22:16:42,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],AMPHOTERICIN B for MYCOSES;,na,71,0,78,77,14,RO-may_prevent,820167-FS1,"AMPHOTERICIN B is no longer used exclusively for classical deep seated MYCOSES; frequently, the drug is used as empiric treatment for candida and aspergillus infections.",MYCOSES,AMPHOTERICIN B
788860309,9/16/2015 01:35:48,1739124511,9/16/2015 01:35:38,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 01:56:38,1739143505,9/16/2015 01:56:23,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[TREATS],[TREATS],treatment,n/a,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:01:26,1739147087,9/16/2015 02:01:13,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:05:05,1739150143,9/16/2015 02:04:40,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],treatment,n/a,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:22:38,1739165246,9/16/2015 02:22:25,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:46:44,1739187559,9/16/2015 02:46:15,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[CAUSES] [SYMPTOM] [NONE],"[CAUSES]
[SYMPTOM]
[NONE]",BJKHG,GHVG HHG,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:53:11,1739193639,9/16/2015 02:51:55,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[PREVENTS],[PREVENTS],DIGITALIS GLYCOSIDES,N/A,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:58:26,1739198267,9/16/2015 02:58:05,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:58:26,1739198278,9/16/2015 02:58:17,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[TREATS] [PREVENTS] [NONE],"[TREATS]
[PREVENTS]
[NONE]",no,no,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 02:59:28,1739199347,9/16/2015 02:59:08,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 03:01:17,1739200822,9/16/2015 03:00:27,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,digitalis is the treatment for infarctions,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 03:22:07,1739219665,9/16/2015 03:21:40,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],CHRONIC CONGESTIVE CARDIAC FAILURE,NONE,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 03:26:41,1739224053,9/16/2015 03:26:13,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],in the treatment of,N/A,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 03:38:34,1739235310,9/16/2015 03:38:06,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],treatment,N/A,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860309,9/16/2015 03:58:54,1739253926,9/16/2015 03:58:12,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],in the treatment of,n/a,112,71,146,170,91,RO-may_prevent,820322-FS1,Atrial was undertaken of assessment of the usefulness and the place of DIGITALIS GLYCOSIDES in the treatment of CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION and in mitral stenosis.,CHRONIC CONGESTIVE CARDIAC FAILURE IN MYOCARDIAL INFARCTION,DIGITALIS GLYCOSIDES
788860310,9/15/2015 23:48:26,1739084157,9/15/2015 23:48:08,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [MANIFESTATION] [CONTRAINDICATES] [LOCATION] [PART_OF] [NONE],"[PREVENTS]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[PART_OF]
[NONE]",ers Drugs for preventing malaria related illness in pregnant women Artemisinin derivatives for treating uncomplicated malaria Insecticide treated bednets and curtains for preventing malaria CHLOROQUINE o,ers Drugs for preventing malaria related illness in pregnant women Artemisinin derivatives for treating uncomplicated malaria Insecticide treated bednets and curtains for preventing malaria CHLOROQUINE o,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 00:17:33,1739091527,9/16/2015 00:16:58,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",for preventing,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 01:05:19,1739105569,9/16/2015 01:04:46,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",for treating,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 01:16:50,1739113020,9/16/2015 01:16:07,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],treating uncomplicated,n/a,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 01:33:05,1739122698,9/16/2015 01:32:51,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PREVENTS],[PREVENTS],preventing,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 01:41:49,1739132140,9/16/2015 01:41:21,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[PREVENTS],[PREVENTS],preventing malaria CHLOROQUINE or amodiaquine combined,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 01:53:12,1739140706,9/16/2015 01:53:00,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treating,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 01:53:28,1739140969,9/16/2015 01:53:03,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],for,n/a,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 01:56:36,1739143451,9/16/2015 01:56:22,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[PREVENTS],[PREVENTS],preventing,n/a,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 02:19:41,1739162576,9/16/2015 02:19:28,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],preventing,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 02:26:56,1739169012,9/16/2015 02:25:41,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],malaria CHLOROQUINE amodiaquine combined with uncomplicated MALARIA,manifestation,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 02:40:34,1739181447,9/16/2015 02:40:08,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[CAUSES] [LOCATION] [NONE],"[CAUSES]
[LOCATION]
[NONE]",GVHGV,GVGHV SZEED,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 02:44:04,1739184996,9/16/2015 02:42:54,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[TREATS],[TREATS],CHLOROQUINE or amodiaquine,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 02:50:14,1739190966,9/16/2015 02:48:42,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],preventing,N/A,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860310,9/16/2015 02:51:21,1739192079,9/16/2015 02:49:49,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,Chloroquine treats malaria.,445,351,349,451,362,RO-may_prevent,820289-FS1,Cochrane Database of Systematic Reviews  WITHDRAWN: Vaccines for preventing malaria  WITHDRAWN: Mefloquine for preventing malaria in non immune adult travellers  Drugs for preventing malaria related illness in pregnant women  Artemisinin derivatives for treating uncomplicated malaria  Insecticide treated bednets and curtains for preventing malaria  CHLOROQUINE or amodiaquine combined with sulfadoxine pyrimethamine for treating uncomplicated MALARIA  Steroids for treating cerebral malaria  Antipyretic measures for treating fever in malaria  Routine anticonvulsants for treating cerebral malaria  High first dose quinine regimen for treating severe malaria  Blood transfusion for treating malarial anaemia  Amodiaquine for treating malaria  Iron chelating agents for treating malaria  WITHDRAWN.,MALARIA,CHLOROQUINE
788860311,9/15/2015 21:09:23,1739018113,9/15/2015 21:08:54,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],GASTRIC ULCERS treated CIMETIDINE,treat,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:11:04,1739020116,9/15/2015 21:10:46,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treated with,N/A,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:11:56,1739021006,9/15/2015 21:11:39,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:15:01,1739024544,9/15/2015 21:14:47,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treated,n/a,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:22:47,1739029849,9/15/2015 21:22:03,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],duodenal treated GASTRIC ULCERS treated with CIMETIDINE,treatment,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:41:20,1739040092,9/15/2015 21:41:00,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treated with,N/A,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:43:51,1739041496,9/15/2015 21:43:24,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",treated with,n/a,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:44:34,1739041855,9/15/2015 21:44:18,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treated,n/a,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:53:32,1739046163,9/15/2015 21:53:04,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[SYMPTOM] [PREVENTS] [TREATS] [PART_OF] [NONE],"[TREATS]
[PREVENTS]
[SYMPTOM]
[PART_OF]
[NONE]",[PREVENTS],N/A,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 21:56:38,1739047482,9/15/2015 21:56:13,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treated,N/A,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 22:22:54,1739057141,9/15/2015 22:22:41,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treated with,n/a,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 22:26:18,1739058076,9/15/2015 22:26:02,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],GASTRIC ULCERS treated with CIMETIDINE,n/a,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 22:31:46,1739059991,9/15/2015 22:30:58,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treated with,N/A,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 22:35:48,1739061406,9/15/2015 22:35:07,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],subjects with GASTRIC ULCERS treated with CIMETIDINE,na,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860311,9/15/2015 22:42:46,1739063634,9/15/2015 22:42:36,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],treated,n/a,252,280,266,265,290,RO-may_prevent,820169-FS1,The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with GASTRIC ULCERS treated with CIMETIDINE,GASTRIC ULCERS,CIMETIDINE
788860312,9/16/2015 03:08:17,1739207396,9/16/2015 03:08:03,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],therapy,Treat,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 03:35:56,1739232789,9/16/2015 03:35:10,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],OSTEOPOROSIS,NONE,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 03:40:15,1739237061,9/16/2015 03:39:22,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],treatment of,N/A,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 04:07:48,1739261986,9/16/2015 04:07:15,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[PREVENTS],[PREVENTS],improvement of muscle strength VITAMIN D OSTEOPOROSIS,N/A,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 04:13:03,1739266935,9/16/2015 04:12:18,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",treatment of to increase,n/a,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 04:19:28,1739273265,9/16/2015 04:19:16,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[NONE],[NONE],nothing,nothing,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 05:15:42,1739330654,9/16/2015 05:14:50,false,elite,1.0,29216801,USA,"","",172.164.36.118,[SIDE_EFFECT],[SIDE_EFFECT],increase,N/A,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 05:18:03,1739332959,9/16/2015 05:17:40,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[PREVENTS],[PREVENTS],non drug therapy,n/a,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 05:21:15,1739336024,9/16/2015 05:19:14,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[PREVENTS],[PREVENTS],non drug therapy include diet rich calcium adequate supply of VITAMIN D OSTEOPOROSIS,n/a,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 05:33:37,1739348680,9/16/2015 05:31:31,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],increase falls or OSTEOPOROSIS,N/A,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 05:58:40,1739377291,9/16/2015 05:58:04,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],therapy,N/A,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 05:58:55,1739377524,9/16/2015 05:58:43,false,neodev,1,34429821,USA,CA,San Jose,50.118.172.120,[NONE],[NONE],[NONE],[NONE],274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 06:13:59,1739389300,9/16/2015 06:13:02,false,gifthunterclub,1,33931170,AUS,04,Brisbane,121.208.7.253,[ASSOCIATED_WITH],[ASSOCIATED_WITH],adequate supply of VITAMIN D,N/A,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 06:15:26,1739390456,9/16/2015 06:13:19,false,clixsense,1.0,31482589,NLD,11,Gouda,77.167.232.121,[OTHER],[OTHER],adequate supply,n/a,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860312,9/16/2015 06:38:03,1739404300,9/16/2015 06:35:58,false,elite,1,29768955,GBR,C3,Gamlingay,31.50.187.165,[TREATS],[TREATS],include adequate supply of,N/A,274,199,286,285,208,RO-may_prevent,820324-FS1,"Components of non drug therapy include improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, adequate supply of VITAMIN D and an individual assessment of drugs known to increase falls or OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860313,9/15/2015 20:57:13,1739005208,9/15/2015 20:56:49,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],MEAN PAIN SCORES LIDOCAINE,effect,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:01:03,1739009765,9/15/2015 21:00:39,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were:,N/A,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:01:41,1739010556,9/15/2015 21:00:53,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],MEAN PAIN SCORES buffered lidocaine.,just treatment,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:01:55,1739010794,9/15/2015 21:01:12,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],for the four solutions,N/A,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:07:45,1739017055,9/15/2015 21:07:28,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MEAN PAIN SCORES for,n/a,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:15:03,1739024589,9/15/2015 21:12:56,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[IS_A],[IS_A],42.2 for,N/A,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:15:56,1739025378,9/15/2015 21:15:34,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:32:09,1739035237,9/15/2015 21:31:56,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:34:55,1739036721,9/15/2015 21:34:31,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],SCORES for,n/a,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:35:59,1739037304,9/15/2015 21:35:29,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SCORES for the solutions,n/a,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:39:08,1739038982,9/15/2015 21:36:14,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],four solutions,N/A,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 21:43:05,1739041012,9/15/2015 21:42:31,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[TREATS] [SYMPTOM] [ASSOCIATED_WITH] [CONTRAINDICATES] [PART_OF] [NONE],"[TREATS]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[PART_OF]
[NONE]",[PREVENTS],N/A,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 22:11:56,1739053272,9/15/2015 22:11:11,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MEAN PAIN SCORES for LIDOCAINE,n/a,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 22:13:22,1739053719,9/15/2015 22:12:25,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[OTHER],[OTHER],SCORES for the four solutions,each variant provides a unique score value,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860313,9/15/2015 22:15:47,1739054576,9/15/2015 22:15:02,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MEAN PAIN SCORES for warmed LIDOCAINE,na,4,92,13,19,101,RO-may_prevent,820326-FS1,"The MEAN PAIN SCORES for the four solutions were: 44.2 for plain lidocaine, 42.2 for warmed LIDOCAINE 36.7 for buffered lidocaine, and 29.2 for warmed, buffered lidocaine.",MEAN PAIN SCORES,LIDOCAINE
788860314,9/16/2015 03:07:41,1739206739,9/16/2015 03:07:06,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,Drug,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 03:34:14,1739231091,9/16/2015 03:33:14,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],MALARIA,NONE,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 03:37:46,1739234560,9/16/2015 03:37:05,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],this drug (Nivaquine) has to be used.,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 03:44:58,1739241420,9/16/2015 03:44:42,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],susceptible,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 04:06:47,1739261033,9/16/2015 04:06:26,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MALARIA susceptible to CHLOROQUINE,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 04:11:30,1739265398,9/16/2015 04:11:02,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],has to be used.,n/a,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 04:18:47,1739272621,9/16/2015 04:18:36,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[ASSOCIATED_WITH] [SIDE_EFFECT] [NONE],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]",nothing,nothing,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 04:40:08,1739294207,9/16/2015 04:38:27,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [OTHER],"[OTHER]
[NONE]",this drug (Nivaquine) has to be used,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 05:16:49,1739331718,9/16/2015 05:15:44,false,elite,1.0,29216801,USA,"","",172.164.36.118,[CONTRAINDICATES],[CONTRAINDICATES],susceptible,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 05:17:21,1739332253,9/16/2015 05:17:05,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],is susceptible to,n/a,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 05:29:12,1739343723,9/16/2015 05:28:49,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",MALARIA is susceptible CHLOROQUINE this drug (Nivaquine) has to be used.,n/a,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 05:29:43,1739344107,9/16/2015 05:28:03,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],MALARIA is susceptible to CHLOROQUINE,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 05:56:48,1739375194,9/16/2015 05:56:23,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],susceptible to,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 05:58:15,1739376858,9/16/2015 05:57:48,false,neodev,1.0,34429821,USA,CA,San Jose,50.118.172.120,[NONE],[NONE],[NONE],[NONE] I don't know,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860314,9/16/2015 06:13:00,1739388559,9/16/2015 06:12:21,false,gifthunterclub,1.0,33931170,AUS,04,Brisbane,121.208.7.253,[OTHER],[OTHER],susceptible,N/A,5,31,12,11,42,RO-may_prevent,820170-FS1,When MALARIA is susceptible to CHLOROQUINE this drug (Nivaquine) has to be used.,MALARIA,CHLOROQUINE
788860315,9/15/2015 20:55:31,1739003396,9/15/2015 20:55:00,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ASTHMA ZAFIRLUKAST asthma.,effect,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 20:59:13,1739007552,9/15/2015 20:57:24,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",ASTHMA inhibited bronchospasm,treatment,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 20:59:30,1739007929,9/15/2015 20:59:16,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],inhibited,N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 20:59:40,1739008061,9/15/2015 20:59:03,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],inhibited,N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:05:24,1739014827,9/15/2015 21:05:08,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASTHMA ZAFIRLUKAST,n/a,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:10:14,1739019130,9/15/2015 21:07:38,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER] [PREVENTS],"[PREVENTS]
[OTHER]",inhibited,N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:12:56,1739021896,9/15/2015 21:12:38,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,[PART_OF],[PART_OF],ASTHMA ZAFIRLUKAST,N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:14:36,1739024081,9/15/2015 21:13:47,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],ASTHMA ZAFIRLUKAST,N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:29:19,1739033595,9/15/2015 21:28:39,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[NONE],[NONE],n/a,two words compromise one term,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:30:54,1739034589,9/15/2015 21:29:34,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],ASTHMA ZAFIRLUKAST,N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:33:23,1739035813,9/15/2015 21:31:24,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[MANIFESTATION],[MANIFESTATION],after,N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:34:44,1739036569,9/15/2015 21:34:00,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[PREVENTS],[PREVENTS],inhibited,n/a,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:41:15,1739040067,9/15/2015 21:40:48,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [MANIFESTATION] [ASSOCIATED_WITH] [NONE],"[PREVENTS]
[MANIFESTATION]
[ASSOCIATED_WITH]
[NONE]",[PREVENTS],N/A,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 21:47:46,1739043589,9/15/2015 21:47:34,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,[NONE],[NONE],n/a,n/a,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860315,9/15/2015 22:10:29,1739052917,9/15/2015 22:09:06,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[PART_OF],[PART_OF],ASTHMA ZAFIRLUKAST inhibited bronchospasm,n/a,22,29,28,27,40,RO-may_prevent,820295-FS1,In clinical models of ASTHMA ZAFIRLUKAST inhibited bronchospasm after allergen or exercise challenge in patients with asthma.,ASTHMA,ZAFIRLUKAST
788860316,9/15/2015 22:27:39,1739058518,9/15/2015 22:27:18,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],induced complications,n/a,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/15/2015 22:52:40,1739066904,9/15/2015 22:52:23,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[SIDE_EFFECT],[SIDE_EFFECT],complications,n/a,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/15/2015 22:58:32,1739068937,9/15/2015 22:57:40,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[CAUSES],[CAUSES],pharmacological therapies,N/A,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/15/2015 23:40:45,1739082288,9/15/2015 23:39:35,false,neodev,1.0,31294288,USA,UT,Providence,206.190.129.237,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",for dysphagia in Parkinson's disease,N/A,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/15/2015 23:42:53,1739082832,9/15/2015 23:42:33,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[MANIFESTATION] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[MANIFESTATION]
[IS_A]
[OTHER]
[NONE]",bad,inson's disease Lisuride for levodopa induced complications in Parkinson's disease Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease Non pharmacological therapies for dysphagia in Parkinson's disease Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE Pramipexole for levodopa induced complications in Parkinson's disease Pramipexole versus bromocr,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/15/2015 23:55:35,1739086267,9/15/2015 23:54:56,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]",in Parkinson's disease,N/A,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 00:22:21,1739092553,9/16/2015 00:22:05,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 00:48:27,1739098822,9/16/2015 00:47:20,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",COMPLICATIONS in,N/A,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 00:52:04,1739099884,9/16/2015 00:50:04,false,clixsense,1.0,22947672,GBR,H9,London,146.198.116.72,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",LEVODOPA INDUCED COMPLICATIONS in PARKINSON'S DISEASE,n/a,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 00:52:17,1739099970,9/16/2015 00:50:32,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[ASSOCIATED_WITH],[ASSOCIATED_WITH],induced complications,n/a,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 00:57:28,1739101492,9/16/2015 00:56:12,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 01:17:11,1739113145,9/16/2015 01:16:32,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[CAUSES],[CAUSES],complications in Parkinson's disease Lisuride for levodopa induced complications,complications in Parkinson's disease Lisuride for levodopa induced complications,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 01:17:20,1739113289,9/16/2015 01:14:45,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],LEVODOPA INDUCED COMPLICATIONS in PARKINSON'S DISEASE induced complications,contraindicates,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 01:22:19,1739116174,9/16/2015 01:22:00,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,[NONE],[NONE],none,n/a,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860316,9/16/2015 01:25:44,1739118302,9/16/2015 01:24:00,false,neodev,1.0,33739202,USA,MS,Madison,75.65.195.220,[LOCATION] [SYMPTOM] [MANIFESTATION] [ASSOCIATED_WITH] [TREATS] [PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [SIDE_EFFECT] [IS_A] [PART_OF] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]
[OTHER]
[NONE]",nolose,omplicaciones en el Parkinson enfermedad Lisuride de levodopa inducida complicaciones en el Parkinson enfermedad Lisuride frente bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad No farmacológicas terapias para la disfagia en el Parkinson enfermedad La pergolida para levodopa INDUCIDA COMPLICACIONES en de Parkinson enfermedad La pergolida en comparación con la bromocriptina para levodopa inducida motor complicaciones en DE PARKINSON ENFERMEDAD El pramipexol de levodopa inducida complicaciones en el Parkinson enfermedad El pramipexol en comparación con la bromocriptina para levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol de levodopa inducida complicaciones en el Parkinson enfermedad Ropinirol frente bromocriptina para levodopa inducida complicaciones en el Parkinson.,407,277,330,425,307,RO-may_treat,820053-FS1,complications in Parkinson's disease  Lisuride for levodopa induced complications in Parkinson's disease  Lisuride versus bromocriptine for levodopa induced complications in Parkinson's disease  Non pharmacological therapies for dysphagia in Parkinson's disease  Pergolide for LEVODOPA INDUCED COMPLICATIONS in Parkinson's disease  Pergolide versus bromocriptine for levodopa induced motor complications in PARKINSON'S DISEASE  Pramipexole for levodopa induced complications in Parkinson's disease  Pramipexole versus bromocriptine for levodopa induced complications in Parkinson's disease  Ropinirole for levodopa induced complications in Parkinson's disease  Ropinirole versus bromocriptine for levodopa induced complications in Parkinson's.,PARKINSON'S DISEASE,LEVODOPA INDUCED COMPLICATIONS
788860317,9/15/2015 21:05:10,1739014605,9/15/2015 21:04:46,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PAIN LIDOCAINE OINTMENT,treat,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:07:44,1739017014,9/15/2015 21:07:13,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treated,N/A,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:08:38,1739017672,9/15/2015 21:08:26,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treated with,N/A,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:13:31,1739022709,9/15/2015 21:13:17,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treated,n/a,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:16:51,1739026202,9/15/2015 21:16:18,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],PAIN treated LIDOCAINE OINTMENT,treatment,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:21:25,1739029146,9/15/2015 21:21:17,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treated,N/A,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:35:53,1739037275,9/15/2015 21:34:53,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treated with,N/A,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:41:10,1739040019,9/15/2015 21:40:54,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],treated with,n/a,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:42:30,1739040709,9/15/2015 21:42:17,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treated,n/a,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:50:24,1739044828,9/15/2015 21:49:46,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[CONTRAINDICATES] [LOCATION] [OTHER] [NONE],"[LOCATION]
[CONTRAINDICATES]
[OTHER]
[NONE]",[PREVENTS],N/A,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 21:51:21,1739045200,9/15/2015 21:50:44,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treated,N/A,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 22:21:07,1739056537,9/15/2015 22:20:57,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treated with,n/a,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 22:23:44,1739057391,9/15/2015 22:23:34,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],PAIN treated with LIDOCAINE OINTMENT,n/a,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 22:26:39,1739058221,9/15/2015 22:26:08,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treated with,N/A,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860317,9/15/2015 22:27:37,1739058517,9/15/2015 22:27:28,false,neodev,1.0,30749660,USA,NC,Wake Forest,71.70.155.5,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",OINTMENT and sitz,n/a,4,26,8,7,44,RO-may_prevent,820296-FS1,The PAIN was treated with LIDOCAINE OINTMENT and sitz baths with partial success.,PAIN,LIDOCAINE OINTMENT
788860318,9/15/2015 23:46:04,1739083569,9/15/2015 23:45:44,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[CAUSES] [SIDE_EFFECT] [SYMPTOM] [LOCATION] [NONE],"[CAUSES]
[LOCATION]
[SYMPTOM]
[SIDE_EFFECT]
[NONE]",bad,"y ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 00:10:41,1739090036,9/16/2015 00:09:58,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is reasonable evidence for the absence of,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 00:57:46,1739101630,9/16/2015 00:56:57,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[ASSOCIATED_WITH],[ASSOCIATED_WITH],reasonable evidence for,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 01:00:58,1739103413,9/16/2015 00:59:37,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],value &gt;25,n/a,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 01:29:10,1739120244,9/16/2015 01:28:24,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],random CORTISOL reasonable evidence absence ADRENAL INSUFFICIENCY.,diagnosed by test or drug,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 01:30:47,1739121193,9/16/2015 01:30:33,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],absence,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 01:32:06,1739122035,9/16/2015 01:31:27,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[PREVENTS],[PREVENTS],CORTISOL value &gt;25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.,CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 01:48:37,1739137373,9/16/2015 01:47:49,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CORTISOL value,n/a,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 01:49:46,1739138290,9/16/2015 01:49:33,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],absence,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 01:51:19,1739139472,9/16/2015 01:51:03,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],absence,n/a,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 02:16:43,1739159848,9/16/2015 02:16:30,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],patient,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 02:36:05,1739177248,9/16/2015 02:35:11,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],insufficiency,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 02:36:17,1739177547,9/16/2015 02:35:44,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[MANIFESTATION] [CONTRAINDICATES] [SIDE_EFFECT] [NONE],"[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",GHHJBJ,FGCG GHVH,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 02:36:39,1739177852,9/16/2015 02:35:45,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[SIDE_EFFECT],[SIDE_EFFECT],ADRENAL INSUFFICIENCY.,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860318,9/16/2015 02:43:50,1739184711,9/16/2015 02:43:04,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[OTHER],[OTHER],absence of,N/A,175,114,76,195,122,RO-may_treat,820054-FS1,"For a critically ill patient thought to be at risk for adrenal insufficiency and with unexplained shock, a random CORTISOL value >25 is reasonable evidence for the absence of ADRENAL INSUFFICIENCY.",ADRENAL INSUFFICIENCY,CORTISOL
788860319,9/15/2015 21:01:39,1739010491,9/15/2015 21:01:17,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],BECLOMETASONE DIPROPIONATE ASTHMA,face,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:05:05,1739014463,9/15/2015 21:04:40,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],recommended,N/A,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:06:02,1739015479,9/15/2015 21:05:19,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],dose,N/A,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:10:44,1739019798,9/15/2015 21:10:25,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",patients with,n/a,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:11:20,1739020349,9/15/2015 21:10:35,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],BECLOMETASONE DIPROPIONATE ASTHMA recommendation,treatment,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:19:15,1739027871,9/15/2015 21:18:59,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],recommended,N/A,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:29:23,1739033632,9/15/2015 21:28:44,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",recommended in,N/A,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:39:12,1739039019,9/15/2015 21:38:56,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],with,n/a,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:40:30,1739039669,9/15/2015 21:40:07,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],recommendation,n/a,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:47:19,1739043352,9/15/2015 21:46:50,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [CAUSES] [ASSOCIATED_WITH] [CONTRAINDICATES] [SYMPTOM] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",[PREVENTS],N/A,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 21:48:04,1739043714,9/15/2015 21:47:32,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],dose,N/A,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 22:19:38,1739056049,9/15/2015 22:19:21,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],currently recommended,n/a,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 22:21:26,1739056656,9/15/2015 22:18:29,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],BECLOMETASONE DIPROPIONATE ASTHMA,n/a,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 22:22:00,1739056877,9/15/2015 22:21:21,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],formulation has been currently recommended,N/A,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860319,9/15/2015 22:23:26,1739057277,9/15/2015 22:22:08,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],BECLOMETASONE DIPROPIONATE formulation recommended in patients with ASTHMA,na,250,157,256,255,183,RO-may_prevent,820176-FS1,"Since the 2  to 3 fold increase in pulmonary deposition results in a 2.6  to 3 fold difference in relative efficacy for Qvar, half the dose of the reference BECLOMETASONE DIPROPIONATE formulation has been currently recommended in adult patients with ASTHMA a recommendation that is supported by a large number of clinical trials.",ASTHMA,BECLOMETASONE DIPROPIONATE
788860320,9/15/2015 23:47:11,1739083869,9/15/2015 23:46:56,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[CAUSES] [CONTRAINDICATES] [SIDE_EFFECT] [OTHER] [NONE],"[CAUSES]
[CONTRAINDICATES]
[SIDE_EFFECT]
[OTHER]
[NONE]",neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of hee,neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of hee,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 00:14:36,1739091001,9/16/2015 00:13:50,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",found ineffective at reducing,N/A,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:00:51,1739103340,9/16/2015 00:59:56,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",reducing,N/A,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:05:50,1739105892,9/16/2015 01:05:03,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],ineffective at reducing,n/a,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:32:04,1739122023,9/16/2015 01:31:39,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],reducing,N/A,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:34:53,1739123968,9/16/2015 01:33:38,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],AMETHOCAINE ineffective reducing PAIN,"no effect, therefore, no real relation",83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:38:10,1739128567,9/16/2015 01:36:55,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[OTHER],[OTHER],AMETHOCAINE was found to be ineffective at reducing the PAIN,AMETHOCAINE was found to be ineffective at reducing the PAIN,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:51:35,1739139641,9/16/2015 01:51:19,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],reducing,N/A,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:51:41,1739139701,9/16/2015 01:51:14,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[OTHER],[OTHER],ineffective,n/a,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 01:52:21,1739140155,9/16/2015 01:52:08,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],ineffective,n/a,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 02:17:44,1739160789,9/16/2015 02:17:31,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],reducing,N/A,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 02:38:26,1739179537,9/16/2015 02:38:00,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[MANIFESTATION] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",DVS,VGRSV BVDF,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 02:39:42,1739180620,9/16/2015 02:39:28,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],reducing,N/A,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 02:40:39,1739181468,9/16/2015 02:40:02,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],AMETHOCAINE,N/A,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860320,9/16/2015 02:47:20,1739188077,9/16/2015 02:45:21,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,Pain is treated by Amethocaine.,83,27,87,86,38,RO-may_prevent,820298-FS1,In the neonatal population AMETHOCAINE was found to be ineffective at reducing the PAIN of heel prick and peripherally inserted central catheters.,PAIN,AMETHOCAINE
788860321,9/15/2015 21:00:17,1739008869,9/15/2015 20:59:52,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],"ANTIGEN (HBSAG) HEPATITIS (HBeAg),",treat,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:03:51,1739013078,9/15/2015 21:03:26,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VIRUS-ASSOCIATED,N/A,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:04:16,1739013479,9/15/2015 21:03:51,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:06:52,1739016305,9/15/2015 21:05:51,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[PART_OF] [SYMPTOM],"[SYMPTOM]
[PART_OF]",All positive hepatitis B surface,there is relation,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:09:56,1739018773,9/15/2015 21:09:33,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:18:03,1739027190,9/15/2015 21:17:39,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],hepatitis surface ANTIGEN (HBSAG) HEPATITIS E,N/A,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:22:07,1739029506,9/15/2015 21:20:57,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],and,N/A,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:38:03,1739038370,9/15/2015 21:37:41,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:39:19,1739039089,9/15/2015 21:38:59,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive,n/a,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:45:54,1739042578,9/15/2015 21:45:28,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [ASSOCIATED_WITH] [SYMPTOM] [CAUSES] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]",[PREVENTS],N/A,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 21:46:26,1739042851,9/15/2015 21:45:33,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 22:16:19,1739054833,9/15/2015 22:15:32,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",ANTIGEN antigen HEPATITIS B VIRUS-ASSOCIATED,n/a,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 22:18:40,1739055753,9/15/2015 22:17:58,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],All were positive for,n/a,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 22:19:24,1739055962,9/15/2015 22:18:33,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[IS_A],[IS_A],VIRUS-ASSOCIATED,N/A,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860321,9/15/2015 22:20:54,1739056451,9/15/2015 22:20:02,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIGEN (HBSAG) HEPATITIS B E and HEPATITIS B VIRUS-ASSOCIATED DNA,na,93,42,105,124,71,RO-may_prevent,820331-FS1,"All were positive for hepatitis B surface ANTIGEN (HBSAG) HEPATITIS B E antigen (HBeAg), and HEPATITIS B VIRUS-ASSOCIATED DNA polymerase (DNA p) for at least 6 months before entry.",HEPATITIS B VIRUS-ASSOCIATED DNA,ANTIGEN (HBSAG) HEPATITIS B E
788860322,9/15/2015 23:46:20,1739083644,9/15/2015 23:46:06,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[TREATS] [SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [NONE] [IS_A] [OTHER],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[IS_A]
[OTHER]
[NONE]",bad,of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 00:11:38,1739090314,9/16/2015 00:10:46,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is attributed,N/A,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 00:58:57,1739102234,9/16/2015 00:57:47,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[NONE],[NONE],N/A,"""lack of an effect"" means no relationship",49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 01:02:11,1739103923,9/16/2015 01:00:59,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],lack of an effect,n/a,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 01:30:11,1739120904,9/16/2015 01:29:11,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],lack of an effect of FLUORIDE on PLAQUE ACID METABOLISM,there was no effect of the drug on the condition,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 01:31:01,1739121320,9/16/2015 01:30:49,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 01:33:33,1739123066,9/16/2015 01:32:07,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",The lack of an effect of FLUORIDE and on PLAQUE ACID METABOLISM,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 01:49:23,1739137947,9/16/2015 01:48:38,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[CAUSES],[CAUSES],effect,n/a,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 01:50:42,1739138968,9/16/2015 01:49:48,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 01:51:35,1739139635,9/16/2015 01:51:20,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],effect,n/a,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 02:16:57,1739160031,9/16/2015 02:16:44,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],attributed,N/A,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 02:36:24,1739177614,9/16/2015 02:36:08,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 02:36:45,1739177881,9/16/2015 02:36:20,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[ASSOCIATED_WITH] [SIDE_EFFECT] [NONE],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]",YIBV,IOJ JHB,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 02:37:32,1739178564,9/16/2015 02:36:41,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FLUORIDE,N/A,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860322,9/16/2015 02:48:55,1739189728,9/16/2015 02:47:21,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,It's ineffective when Flouride is used.,49,25,55,70,33,RO-may_prevent,820210-FS1,The lack of an effect of FLUORIDE and xylitol on PLAQUE ACID METABOLISM is attributed to the variability of dental plaque and the low concentrations of active ingredients reaching the plaque.,PLAQUE ACID METABOLISM,FLUORIDE
788860323,9/15/2015 21:01:16,1739010015,9/15/2015 21:00:56,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],HBSAG HEPATITIS B,what,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:04:38,1739013957,9/15/2015 21:04:16,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[PREVENTS],[PREVENTS],effectiveness.,N/A,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:05:17,1739014731,9/15/2015 21:04:36,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:10:24,1739019403,9/15/2015 21:10:11,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],dependent and vaccination,n/a,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:10:34,1739019616,9/15/2015 21:08:36,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",HBSAG HEPATITIS low effectiveness.,not effective,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:18:58,1739027712,9/15/2015 21:18:30,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:28:40,1739033209,9/15/2015 21:27:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,Their relation cannot be highlighted in the sentence.,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:38:55,1739038887,9/15/2015 21:38:23,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],against,n/a,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:40:06,1739039437,9/15/2015 21:39:36,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],immune response,n/a,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:46:48,1739043060,9/15/2015 21:46:23,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[LOCATION] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[NONE]",[PREVENTS],N/A,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 21:47:31,1739043442,9/15/2015 21:46:58,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",vaccination,N/A,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 22:18:27,1739055661,9/15/2015 22:18:03,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HBSAG vaccination against HEPATITIS B,n/a,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 22:19:20,1739055949,9/15/2015 22:18:54,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],vaccination,n/a,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 22:21:20,1739056618,9/15/2015 22:20:12,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[LOCATION],[LOCATION],T cell,N/A,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860323,9/15/2015 22:26:34,1739058206,9/15/2015 22:25:23,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],HBSAG against HEPATITIS B is of low effectiveness.,na,85,28,96,95,33,RO-may_prevent,820213-FS1,The immune response against HBSAG is helper T cell dependent and vaccination against HEPATITIS B is of low effectiveness.,HEPATITIS B,HBSAG
788860324,9/15/2015 21:09:57,1739018783,9/15/2015 21:09:25,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],MALARIA CHLOROQUINE,prevent,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:11:55,1739020964,9/15/2015 21:11:22,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[OTHER],[OTHER],administered to,N/A,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:12:29,1739021487,9/15/2015 21:12:02,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],interference,N/A,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:15:25,1739024961,9/15/2015 21:15:01,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],MALARIA CHLOROQUINE,n/a,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:24:39,1739030975,9/15/2015 21:22:48,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS] [SYMPTOM],"[TREATS]
[SYMPTOM]",interference from drugs commonly,there is relation,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:42:05,1739040481,9/15/2015 21:41:24,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],drugs commonly administered,N/A,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:44:22,1739041760,9/15/2015 21:43:53,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[CONTRAINDICATES],[CONTRAINDICATES],drugs commonly administered,n/a,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:44:51,1739042020,9/15/2015 21:44:36,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],administered,n/a,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:54:01,1739046449,9/15/2015 21:53:34,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [PART_OF] [CONTRAINDICATES] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]
[PART_OF]
[NONE]",[PREVENTS],N/A,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 21:57:03,1739047641,9/15/2015 21:56:38,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],administered,N/A,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 22:23:19,1739057254,9/15/2015 22:22:55,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],commonly administered,n/a,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 22:26:31,1739058194,9/15/2015 22:26:19,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],"MALARIA CHLOROQUINE quinine,",n/a,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 22:32:19,1739060204,9/15/2015 22:31:48,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],drugs commonly administered,N/A,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 22:36:43,1739061716,9/15/2015 22:36:00,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],"drugs commonly administered with severe MALARIA CHLOROQUINE quinine,",na,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860324,9/15/2015 22:43:11,1739063721,9/15/2015 22:42:48,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],administered,n/a,83,119,90,89,130,RO-may_prevent,820183-FS1,"There was no interference from drugs commonly administered to children with severe MALARIA (phenobarbitone, phenytoin, CHLOROQUINE quinine, sulfadoxine, pyrimethamine, halofantrine, cycloguanil, chlorcycloguanil, acetaminophen and salicylate.",MALARIA,CHLOROQUINE
788860325,9/15/2015 23:46:53,1739083785,9/15/2015 23:46:40,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [ASSOCIATED_WITH] [PART_OF] [CONTRAINDICATES] [SIDE_EFFECT] [LOCATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]
[NONE]",bad,IMETIDINE was cost effective in both gastric ulcer and DUODENAL ULCER patients in the fi,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 00:13:44,1739090817,9/16/2015 00:12:42,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",had elected to proceed,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 00:59:55,1739102876,9/16/2015 00:59:26,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",proceed to,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 01:05:02,1739105396,9/16/2015 01:03:43,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],had elected to proceed,n/a,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 01:31:37,1739121681,9/16/2015 01:31:25,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],proceed,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 01:33:37,1739123135,9/16/2015 01:32:36,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],MORPHINE RESISTANT PAIN to proceed to INTRATHECAL BUPIVACAINE,treats,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 01:36:53,1739126109,9/16/2015 01:34:08,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],MORPHINE RESISTANT PAIN and had elected proceed INTRATHECAL BUPIVACAINE,MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 01:51:13,1739139402,9/16/2015 01:49:55,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],appeared,n/a,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 01:51:16,1739139432,9/16/2015 01:51:04,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],proceed,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 01:52:08,1739139967,9/16/2015 01:51:52,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],elected to proceed,n/a,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 02:17:30,1739160603,9/16/2015 02:17:12,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],proceed,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 02:37:57,1739178955,9/16/2015 02:37:22,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[MANIFESTATION] [SIDE_EFFECT] [ASSOCIATED_WITH] [NONE],"[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]",VHYHGY,HYYHB BYB,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 02:39:27,1739180382,9/16/2015 02:39:13,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],proceed,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 02:40:00,1739180906,9/16/2015 02:39:15,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[IS_A],[IS_A],INTRATHECAL BUPIVACAINE,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860325,9/16/2015 02:45:20,1739186286,9/16/2015 02:44:36,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[OTHER],[OTHER],proceed to,N/A,30,84,53,52,107,RO-may_prevent,820187-FS1,All patients appeared to have MORPHINE RESISTANT PAIN and had elected to proceed to INTRATHECAL BUPIVACAINE or percutaneous cordotomy.,MORPHINE RESISTANT PAIN,INTRATHECAL BUPIVACAINE
788860326,9/15/2015 20:56:47,1739004784,9/15/2015 20:56:14,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[MANIFESTATION],[MANIFESTATION],"VII); ASPIRIN, FEVER (Gr VIII.",prevent,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:00:37,1739009276,9/15/2015 21:00:08,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assignment,N/A,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:00:51,1739009544,9/15/2015 21:00:15,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","aspirin ASPIRIN, FEVER fasting",treatment,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:01:11,1739009909,9/15/2015 20:59:56,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[OTHER],[OTHER],Random assignment,N/A,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:06:54,1739016318,9/15/2015 21:06:16,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"and ASPIRIN, FEVER",n/a,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:12:52,1739021861,9/15/2015 21:11:37,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],(Gr VIII.,N/A,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:15:33,1739025103,9/15/2015 21:15:06,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],administration,N/A,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:31:54,1739035080,9/15/2015 21:31:34,false,neodev,1,30504276,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],aspirin administration,N/A,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:34:30,1739036464,9/15/2015 21:34:13,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],and,n/a,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:35:29,1739036996,9/15/2015 21:35:12,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],administration,n/a,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:36:13,1739037417,9/15/2015 21:34:27,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],administration,N/A,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:42:30,1739040719,9/15/2015 21:42:03,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[NONE]",[PREVENTS],N/A,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 21:48:07,1739043737,9/15/2015 21:47:59,false,prodege,1,2143114,CAN,BC,Vancouver,24.85.153.181,[TREATS],[TREATS],Control,n/a,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 22:11:10,1739053082,9/15/2015 22:10:30,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],"fever ASPIRIN,",n/a,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860326,9/15/2015 22:11:44,1739053210,9/15/2015 22:10:31,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],"ASPIRIN, FEVER",Na,242,233,189,246,240,RO-may_treat,820100-FS1,"Random assignment was made to eight groups (Grs): Control (Gr I); aspirin administration only (Gr II); fasting only (Gr III); fever only (Gr IV); aspirin and fever (Gr V); fasting and fever (Gr VI); aspirin and fasting (Gr VII); and ASPIRIN, FEVER and fasting (Gr VIII.",FEVER,ASPIRIN
788860327,9/15/2015 21:04:06,1739013289,9/15/2015 21:03:34,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],LEVOTHYROXINE HYPOTHYROIDISM,prevent,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:06:28,1739015978,9/15/2015 21:06:13,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:07:29,1739016787,9/15/2015 21:07:14,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment of,N/A,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:12:45,1739021725,9/15/2015 21:12:35,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treatment,n/a,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:14:59,1739024506,9/15/2015 21:14:04,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],preparations for treatment,tretment,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:20:28,1739028613,9/15/2015 21:20:11,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:33:56,1739036133,9/15/2015 21:32:57,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:40:23,1739039629,9/15/2015 21:40:08,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[TREATS],[TREATS],treatment,n/a,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:41:52,1739040363,9/15/2015 21:41:41,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:49:14,1739044270,9/15/2015 21:48:45,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [OTHER] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[OTHER]
[NONE]",[PREVENTS],N/A,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 21:50:18,1739044743,9/15/2015 21:49:44,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 22:20:40,1739056371,9/15/2015 22:20:27,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 22:22:56,1739057163,9/15/2015 22:22:36,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,n/a,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 22:24:56,1739057725,9/15/2015 22:24:36,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860327,9/15/2015 22:27:16,1739058408,9/15/2015 22:26:35,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],LEVOTHYROXINE for treatment of HYPOTHYROIDISM,na,62,18,76,75,31,RO-may_prevent,820342-FS1,Bioequivalence of LEVOTHYROXINE preparations for treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
788860328,9/16/2015 03:06:41,1739206027,9/16/2015 03:06:04,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,Asdociated,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 03:12:26,1739210797,9/16/2015 03:11:58,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[OTHER],[OTHER],inhibited by,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 03:32:24,1739229387,9/16/2015 03:31:24,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],AIRWAY INFLAMMATION,NONE,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 03:36:10,1739232993,9/16/2015 03:35:23,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[SIDE_EFFECT],[SIDE_EFFECT],reactions and the associated increase,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 03:44:07,1739240595,9/16/2015 03:43:44,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],whether they are inhibited,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 04:05:59,1739260338,9/16/2015 04:05:29,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[ASSOCIATED_WITH],[ASSOCIATED_WITH],linked to AIRWAY INFLAMMATION investigated inhibited by PREDNISONE,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 04:10:14,1739264147,9/16/2015 04:08:03,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",are linked to inhibited by,n/a,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 04:18:04,1739271806,9/16/2015 04:17:50,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[LOCATION] [SYMPTOM] [CONTRAINDICATES] [NONE],"[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[NONE]",none,none,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 04:29:52,1739283160,9/16/2015 04:29:45,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,[TREATS],[TREATS],INFLAMMATION,It makes sense,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 04:35:35,1739289546,9/16/2015 04:33:54,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [SIDE_EFFECT],"[SIDE_EFFECT]
[NONE]",inhibited,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 05:14:15,1739329238,9/16/2015 05:13:51,false,elite,1.0,29216801,USA,"","",172.164.36.118,[ASSOCIATED_WITH],[ASSOCIATED_WITH],linked,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 05:16:41,1739331584,9/16/2015 05:16:19,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[PREVENTS],[PREVENTS],inhibited by,n/a,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 05:23:41,1739338122,9/16/2015 05:21:17,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[OTHER],[OTHER],determine whether asthmatic reactions responsiveness induced toluene diisocyanate (TDI) linked AIRWAY INFLAMMATION investigated whether inhibited PREDNISONE,n/a,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 05:26:49,1739341230,9/16/2015 05:24:21,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],inhibited by PREDNISONE,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860328,9/16/2015 05:57:33,1739376082,9/16/2015 05:56:49,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],inhibited by,N/A,151,217,170,169,227,RO-may_treat,820101-FS1,To determine whether late asthmatic reactions and the associated increase in airway responsiveness induced by toluene diisocyanate (TDI) are linked to AIRWAY INFLAMMATION we investigated whether they are inhibited by PREDNISONE,AIRWAY INFLAMMATION,PREDNISONE
788860329,9/15/2015 20:57:37,1739005735,9/15/2015 20:57:14,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],FAMCICLOVIR GENITAL HERPES,treat,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:01:26,1739010211,9/15/2015 21:01:06,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:02:13,1739011189,9/15/2015 21:01:55,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],efficacy in the suppression of,N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:02:14,1739011201,9/15/2015 21:01:42,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],FAMCICLOVIR GENITAL HERPES treatment,treatment,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:08:15,1739017315,9/15/2015 21:07:57,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],recurrent episodes of,n/a,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:15:32,1739025053,9/15/2015 21:15:06,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[PREVENTS],[PREVENTS],suppression of,N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:16:13,1739025639,9/15/2015 21:15:57,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],suppression,N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:32:33,1739035437,9/15/2015 21:32:10,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],suppression,N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:35:19,1739036893,9/15/2015 21:34:57,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],recurrent episodes of,n/a,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:36:15,1739037420,9/15/2015 21:36:00,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[PREVENTS],[PREVENTS],suppression,n/a,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:40:06,1739039439,9/15/2015 21:39:09,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],suppression,N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 21:43:32,1739041322,9/15/2015 21:43:06,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [LOCATION] [SIDE_EFFECT] [NONE],"[PREVENTS]
[LOCATION]
[SIDE_EFFECT]
[NONE]",[PREVENTS],N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 22:12:18,1739053391,9/15/2015 22:11:57,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],FAMCICLOVIR in suppression of episodes of GENITAL HERPES,n/a,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 22:14:59,1739054324,9/15/2015 22:13:54,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[PREVENTS],[PREVENTS],FAMCICLOVIR has efficacy in suppression of GENITAL HERPES,na,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860329,9/15/2015 22:15:09,1739054376,9/15/2015 22:13:23,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],suppression of,N/A,74,0,88,87,11,RO-may_prevent,820189-FS1,"FAMCICLOVIR also has efficacy in the suppression of recurrent episodes of GENITAL HERPES and in the treatment of orolabial herpes, in immunocompetent patients.",GENITAL HERPES,FAMCICLOVIR
788860330,9/15/2015 23:44:02,1739083062,9/15/2015 23:43:49,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[SYMPTOM] [CAUSES] [SIDE_EFFECT] [PART_OF] [NONE],"[CAUSES]
[SYMPTOM]
[SIDE_EFFECT]
[PART_OF]
[NONE]",bad,"fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in child",286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 00:05:22,1739088563,9/16/2015 00:04:41,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"later, bronchitis, pneumonia",N/A,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 00:26:26,1739093430,9/16/2015 00:24:35,false,neodev,1.0,31294288,USA,NJ,East Brunswick,69.248.85.124,[SYMPTOM],[SYMPTOM],Delayed onset of symptoms with nitrogen oxides,N/A,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 00:52:18,1739099971,9/16/2015 00:50:26,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",as soon as symptoms develop;,N/A,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 00:56:00,1739101002,9/16/2015 00:54:38,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],as soon as symptoms develop;,n/a,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:04:03,1739104833,9/16/2015 01:03:04,false,clixsense,1.0,32049531,USA,DE,Wilmington,199.115.115.210,[NONE],[NONE],none,none,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:22:38,1739116401,9/16/2015 01:21:37,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],PULMONARY EDEMA; O2 as soon as symptoms develop;,treats,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:23:14,1739116716,9/16/2015 01:21:04,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[SYMPTOM],[SYMPTOM],PULMONARY EDEMA; O2 as soon as symptoms develop;,"PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop",286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:28:36,1739119988,9/16/2015 01:27:24,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[TREATS],[TREATS],PULMONARY EDEMA; O2,n/a,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:29:18,1739120340,9/16/2015 01:29:05,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PREVENTS],[PREVENTS],liberated,N/A,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:43:30,1739133479,9/16/2015 01:43:04,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],symptoms,N/A,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:44:50,1739134554,9/16/2015 01:44:08,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[SYMPTOM],[SYMPTOM],symptoms,n/a,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:48:02,1739136973,9/16/2015 01:47:49,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],symptoms,N/A,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 01:49:28,1739137990,9/16/2015 01:48:59,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],as soon as,n/a,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860330,9/16/2015 02:15:15,1739158420,9/16/2015 02:13:50,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[MANIFESTATION],[MANIFESTATION],Delayed,N/A,286,342,301,300,344,RO-may_prevent,820224-FS1,"57) Air contaminants that form atmospheric oxidants and that were liberated from missile fuels, explosives, or agricultural wastes Cobaltous chloride Hydrogen chloride Hydrogen fluoride Delayed onset of symptoms with nitrogen oxides unless heavy concentration; fatigue, cough, dyspnea, PULMONARY EDEMA; later, bronchitis, pneumonia Bed rest; O2 as soon as symptoms develop; for excessive pulmonary foam: suction, postural drainage, tracheotomy; prednisone 30 80 mg/day in adults and dexamethasone 1 mg/m2 BSA in children to possibly prevent pulmonary fibrosis Nitroglycerin See Nitrites       Nitroprusside See.",PULMONARY EDEMA,O2
788860331,9/15/2015 20:59:22,1739007724,9/15/2015 20:58:48,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO,treat,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:02:56,1739012056,9/15/2015 21:02:19,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],represented,N/A,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:03:23,1739012507,9/15/2015 21:02:51,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[ASSOCIATED_WITH],[ASSOCIATED_WITH],no significant difference between,N/A,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:05:10,1739014586,9/15/2015 21:04:09,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],NONSMOKING ASTHMATIC PATIENTS therapy BECLOMETHASONE,treatment,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:09:12,1739017998,9/15/2015 21:09:00,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],micrograms,n/a,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:17:17,1739026543,9/15/2015 21:16:58,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],receiving,N/A,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:19:18,1739027893,9/15/2015 21:17:43,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],therapy,N/A,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:37:18,1739037948,9/15/2015 21:36:49,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],WHO WERE receiving,n/a,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:37:53,1739038266,9/15/2015 21:37:27,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],no significant difference,n/a,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:43:32,1739041321,9/15/2015 21:42:57,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],receiving,N/A,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 21:44:53,1739042033,9/15/2015 21:44:27,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [MANIFESTATION] [IS_A] [SIDE_EFFECT] [NONE],"[PREVENTS]
[MANIFESTATION]
[SIDE_EFFECT]
[IS_A]
[NONE]",[PREVENTS],N/A,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 22:15:01,1739054333,9/15/2015 22:14:05,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[OTHER],[OTHER],NONSMOKING ASTHMATIC PATIENTS receiving BECLOMETHASONE,n/a,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 22:17:22,1739055230,9/15/2015 22:16:21,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],receiving inhaled therapy,N/A,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 22:17:38,1739055361,9/15/2015 22:17:18,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],receiving inhaled,n/a,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860331,9/15/2015 22:19:10,1739055864,9/15/2015 22:18:11,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],NONSMOKING ASTHMATIC PATIENTS receiving BECLOMETHASONE,na,69,179,99,116,193,RO-may_prevent,820227-FS1,"We found no significant difference between the LC 1 concentration in BALF FROM NONSMOKING ASTHMATIC PATIENTS WHO WERE receiving inhaled glucocorticoid therapy (2 x 100 micrograms BECLOMETHASONE 4 times/day for 2.5 yr; median 186 ng LC 1/mg albumin; n = 6) and those who were not (median 126 ng LC 1/mg albumin; n = 12), perhaps because inhaled drugs deposit predominantly in central airways, which are poorly represented in bronchoalveolar lavage.",NONSMOKING ASTHMATIC PATIENTS,BECLOMETHASONE
788860332,9/15/2015 22:24:09,1739057509,9/15/2015 22:23:55,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],provided,n/a,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 22:27:35,1739058507,9/15/2015 22:27:18,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],CHLOROQUINE TREATMENT FOR MALARIA,n/a,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 22:35:10,1739061166,9/15/2015 22:34:09,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],TREATMENT FOR,N/A,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 22:38:42,1739062457,9/15/2015 22:38:08,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],CHLOROQUINE TREATMENT FOR MALARIA,na,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 22:44:21,1739064106,9/15/2015 22:44:04,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],TREATMENT,n/a,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 22:47:43,1739065141,9/15/2015 22:46:07,false,prodege,1.0,34294822,USA,TX,Allen,99.7.230.126,[TREATS],[TREATS],provided,N/A,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 22:49:17,1739065620,9/15/2015 22:47:58,false,clixsense,1.0,6330007,AUS,"","",101.178.25.217,[TREATS],[TREATS],provided TREATMENT,n/a,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 22:53:33,1739067234,9/15/2015 22:52:07,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[OTHER],[OTHER],in each village,N/A,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 23:14:51,1739074567,9/15/2015 23:14:26,false,clixsense,1.0,31580375,GBR,H4,Leicester,5.67.162.207,[TREATS],[TREATS],TREATMENT,n/a,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 23:30:43,1739079351,9/15/2015 23:29:22,false,elite,1.0,31722487,USA,UT,Providence,206.190.129.237,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",provided,N/A,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 23:33:48,1739080263,9/15/2015 23:31:52,false,neodev,1.0,31294288,USA,UT,Providence,206.190.129.237,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",provided,N/A,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/15/2015 23:38:56,1739081752,9/15/2015 23:36:19,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[MANIFESTATION] [LOCATION] [CAUSES] [SYMPTOM] [TREATS] [SIDE_EFFECT] [CONTRAINDICATES] [IS_A] [PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[SYMPTOM]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[IS_A]
[OTHER]
[NONE]",malaria,malaria is very dangerous,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/16/2015 00:01:13,1739087660,9/15/2015 23:59:42,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[OTHER],[OTHER],provided,N/A,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/16/2015 00:19:24,1739091916,9/16/2015 00:18:50,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[PART_OF],[PART_OF],provided,N/A,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860332,9/16/2015 00:42:35,1739097383,9/16/2015 00:41:53,false,clixsense,1.0,22947672,GBR,H9,London,146.198.116.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MALARIA CONTROL PROGRAMME in Kenya provided CHLOROQUINE TREATMENT FOR MALARIA,n/a,18,72,25,42,105,RO-may_prevent,820229-FS1,"A community based MALARIA CONTROL PROGRAMME in Saradidi, Kenya provided CHLOROQUINE TREATMENT FOR MALARIA in each village beginning in May 1982.",MALARIA CONTROL PROGRAMME,CHLOROQUINE TREATMENT FOR MALARIA
788860333,9/15/2015 20:59:51,1739008297,9/15/2015 20:59:24,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[MANIFESTATION],[MANIFESTATION],METFORMIN: TYPE DIABETES MELLITUS,worries,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:03:24,1739012508,9/15/2015 21:02:57,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Tests,N/A,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:03:48,1739013003,9/15/2015 21:03:25,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Tests,N/A,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:05:50,1739015244,9/15/2015 21:05:10,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],METFORMIN: diagnosis TYPE 2 DIABETES MELLITUS,diagnosing,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:09:32,1739018241,9/15/2015 21:09:13,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis,n/a,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:17:38,1739026886,9/15/2015 21:17:18,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:20:52,1739028816,9/15/2015 21:19:21,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:37:39,1739038153,9/15/2015 21:37:19,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:38:57,1739038879,9/15/2015 21:37:54,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],update,n/a,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:45:26,1739042328,9/15/2015 21:44:55,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[TREATS] [CAUSES] [MANIFESTATION] [IS_A] [PART_OF] [NONE],"[TREATS]
[CAUSES]
[MANIFESTATION]
[IS_A]
[PART_OF]
[NONE]",[PREVENTS],N/A,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 21:45:32,1739042377,9/15/2015 21:43:33,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Tests,N/A,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 22:15:30,1739054485,9/15/2015 22:15:02,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],METFORMIN: diagnosis of TYPE 2 DIABETES MELLITUS,n/a,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 22:17:57,1739055468,9/15/2015 22:17:39,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",update Tests,n/a,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 22:18:32,1739055672,9/15/2015 22:17:23,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],Effect of a multivitamin and mineral supplement,N/A,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860333,9/15/2015 22:20:00,1739056153,9/15/2015 22:19:11,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],METFORMIN: Tests of glycemia for diagnosis of TYPE 2 DIABETES MELLITUS,na,61,0,85,84,9,RO-may_treat,820072-FS1,METFORMIN: an update  Tests of glycemia for the diagnosis of TYPE 2 DIABETES MELLITUS  Effect of a multivitamin and mineral supplement on infection and quality of life.,TYPE 2 DIABETES MELLITUS,METFORMIN
788860334,9/16/2015 02:49:05,1739189956,9/16/2015 02:48:44,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[MANIFESTATION] [LOCATION] [PREVENTS] [NONE],"[PREVENTS]
[LOCATION]
[MANIFESTATION]
[NONE]",HBJ,XDFDXC JKNJKN,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 02:57:53,1739197862,9/16/2015 02:57:02,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",VITAMIN D,N/A,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 03:03:43,1739203099,9/16/2015 03:03:17,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[PREVENTS],[PREVENTS],prevention,Prevent,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 03:06:16,1739205610,9/16/2015 03:06:09,false,neodev,1.0,34431172,USA,NY,New York,162.243.160.236,[CAUSES] [NONE],"[CAUSES]
[NONE]",no,no,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 03:06:32,1739205828,9/16/2015 03:05:17,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,vitamin d treats osteoporosis,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 03:07:48,1739206897,9/16/2015 03:07:26,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],in,N/A,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 03:26:18,1739223713,9/16/2015 03:25:33,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[LOCATION],[LOCATION],OSTEOPOROSIS,NONE,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 03:31:06,1739228108,9/16/2015 03:30:31,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[PREVENTS],[PREVENTS],in the prevention of,N/A,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 03:40:38,1739237353,9/16/2015 03:40:19,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],in the treatment of,N/A,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 04:02:49,1739257473,9/16/2015 04:02:23,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],use of VITAMIN D in treatment of OSTEOPOROSIS,N/A,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 04:03:15,1739258017,9/16/2015 04:02:26,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",the prevention of use of treatment of,n/a,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 04:15:28,1739269504,9/16/2015 04:15:12,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[ASSOCIATED_WITH] [CAUSES] [NONE],"[CAUSES]
[ASSOCIATED_WITH]
[NONE]",ninguno,ninguno,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 04:24:20,1739277787,9/16/2015 04:23:06,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [TREATS],"[TREATS]
[NONE]",the use of calcium,N/A,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 04:27:46,1739281128,9/16/2015 04:25:11,false,bitcoinget,1,21678835,USA,OH,Ironton,76.177.160.209,[PREVENTS],[PREVENTS],prevention treatment,NA,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860334,9/16/2015 04:28:17,1739281565,9/16/2015 04:27:48,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,[TREATS],[TREATS],prevention,It makes sense,305,255,317,316,264,RO-may_prevent,820230-FS1,"The government produced frameworks mirror guidelines produced by the profession and include a number of prescribing recommendations, e.g. the use of antihypertensives and aspirin (acetylsalicylic acid) in the prevention of stroke, and the use of calcium, VITAMIN D and bisphosphonates in the treatment of OSTEOPOROSIS",OSTEOPOROSIS,VITAMIN D
788860335,9/16/2015 03:04:28,1739203961,9/16/2015 03:04:07,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 03:08:55,1739207931,9/16/2015 03:07:30,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,Pain was less effective with aspirin.,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 03:27:44,1739224965,9/16/2015 03:27:02,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],iloprost,NONE,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 03:32:44,1739229778,9/16/2015 03:31:51,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],iloprost treatment had complete relief of,N/A,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 03:42:21,1739238794,9/16/2015 03:41:22,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],complete relief of,N/A,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 04:04:01,1739258546,9/16/2015 04:03:21,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],relief of PAIN on ASPIRIN,N/A,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 04:05:31,1739259759,9/16/2015 04:03:51,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",had compared with,n/a,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 04:16:20,1739270263,9/16/2015 04:15:56,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[NONE]",nothong,nothing,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 04:28:05,1739281396,9/16/2015 04:27:10,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [TREATS],"[TREATS]
[NONE]",eatment had complete relief of,N/A,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 04:28:48,1739282065,9/16/2015 04:28:34,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,[TREATS],[TREATS],PAIN,It makes sense,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 04:51:29,1739306042,9/16/2015 04:50:26,false,neodev,1.0,33739744,USA,VA,Manassas,207.244.83.121,[CAUSES] [SYMPTOM] [NONE] [OTHER],"[CAUSES]
[SYMPTOM]
[OTHER]
[NONE]",causes and symptoms are related,N/a,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 05:10:11,1739325051,9/16/2015 05:09:02,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[TREATS],[TREATS],relief of PAIN compared with (28%) ASPIRIN,N/A,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 05:12:10,1739327175,9/16/2015 05:11:06,false,elite,1.0,29216801,USA,"","",172.164.36.118,[TREATS],[TREATS],treatment,N/A,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 05:14:59,1739329937,9/16/2015 05:14:46,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],on,n/a,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860335,9/16/2015 05:16:15,1739331149,9/16/2015 05:15:50,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,54,85,58,57,92,RO-may_prevent,820197-FS1,43 (63%) on iloprost treatment had complete relief of PAIN compared with 18 (28%) on ASPIRIN,PAIN,ASPIRIN
788860336,9/15/2015 20:54:57,1739002880,9/15/2015 20:54:17,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],PTT; WAVE MYOCARDIAL INFARCTION; STANDARD HEPARIN;,prevent,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 20:57:23,1739005457,9/15/2015 20:56:19,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],Q WAVE MYOCARDIAL INFARCTION; STANDARD HEPARIN;,just  treat,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 20:59:02,1739007365,9/15/2015 20:57:10,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[CAUSES],[CAUSES],weight,N/A,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 20:59:15,1739007586,9/15/2015 20:58:24,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[PREVENTS],[PREVENTS],Primary prevention;,N/A,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:05:07,1739014534,9/15/2015 21:04:48,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MYOCARDIAL INFARCTION; STANDARD HEPARIN;,n/a,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:07:25,1739016669,9/15/2015 21:05:44,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,There's no relation. It's just a list.,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:12:37,1739021591,9/15/2015 21:12:06,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,[NONE],[NONE],N/A,It's just a list,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:13:45,1739023013,9/15/2015 21:13:21,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[PART_OF],[PART_OF],"Stimulators,",N/A,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:28:37,1739033174,9/15/2015 21:27:57,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[NONE],[NONE],n/a,it's just a list of items,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:29:33,1739033753,9/15/2015 21:28:41,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[NONE],[NONE],N/A,N/A,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:31:23,1739034836,9/15/2015 21:30:41,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[PREVENTS],[PREVENTS],Preventive measures;,N/A,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:33:59,1739036180,9/15/2015 21:33:05,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],Medication;,n/a,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:40:46,1739039820,9/15/2015 21:40:28,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[CAUSES] [MANIFESTATION] [CONTRAINDICATES] [NONE],"[CAUSES]
[MANIFESTATION]
[CONTRAINDICATES]
[NONE]",[PREVENTS],N/A,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 21:47:33,1739043446,9/15/2015 21:46:56,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,[NONE],[NONE],n/a,n/a,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860336,9/15/2015 22:13:53,1739053985,9/15/2015 22:11:58,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Q WAVE MYOCARDIAL INFARCTION; STANDARD HEPARIN;,na,380,455,408,407,471,RO-may_treat,820077-FS1,"Lovenox; Low molecular weight heparin; Medication; MI   myocardial infarction; Monitoring; Myocardial infarction; Myocardial ischemia; New onset angina; Non Q wave MI; Pacemakers; Partial thromboplastin time; Persistent ST segment elevation; Postoperative MI; Pre exposure prophylaxis; Preoperative ischemia; Prevention; Preventive measures; Primary prevention; Prophylaxis; PTT; Q WAVE MYOCARDIAL INFARCTION; Safety; South America; ST segment elevation; STANDARD HEPARIN; Stimulators, cardiac; Subcutaneous low molecular weight heparin; Tedelparin; Thrombocytopenia.",Q WAVE MYOCARDIAL INFARCTION,STANDARD HEPARIN
788860337,9/16/2015 03:05:20,1739204832,9/16/2015 03:04:55,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],nonr,None,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 03:10:51,1739209561,9/16/2015 03:10:14,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,malaria is treated by chlorquine phosphate,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 03:29:13,1739226421,9/16/2015 03:28:24,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],MALARIA,NONE,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 03:34:01,1739230928,9/16/2015 03:33:24,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],All persons receive 600 mg,N/A,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 03:42:57,1739239444,9/16/2015 03:42:43,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],receive 600 mg at the clinic,N/A,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 04:04:44,1739259174,9/16/2015 04:04:24,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],persons with MALARIA receive CHLOROQUINE PHOSPHATE,N/A,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 04:06:45,1739261028,9/16/2015 04:06:19,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],receive,n/a,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 04:17:19,1739271077,9/16/2015 04:16:43,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[PREVENTS] [SYMPTOM] [ASSOCIATED_WITH] [NONE],"[PREVENTS]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]",nothing,nothing,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 04:29:19,1739282626,9/16/2015 04:29:09,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,[TREATS],[TREATS],600 CHLOROQUINE,It makes sense,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 04:31:31,1739284961,9/16/2015 04:29:27,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [TREATS],"[TREATS]
[NONE]",receive,N/A,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 04:52:39,1739307029,9/16/2015 04:52:03,false,neodev,1.0,33739744,USA,VA,Manassas,207.244.83.121,[NONE] [OTHER],"[OTHER]
[NONE]",N/a,I did not find any relationship,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 05:12:57,1739327792,9/16/2015 05:12:36,false,elite,1.0,29216801,USA,"","",172.164.36.118,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],receive,N/A,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 05:13:17,1739328163,9/16/2015 05:11:47,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[TREATS],[TREATS],All with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE,N/A,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 05:15:45,1739330704,9/16/2015 05:15:24,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],receive a prescription,n/a,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860337,9/16/2015 05:19:46,1739334667,9/16/2015 05:18:11,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],MALARIA receive 600 mg CHLOROQUINE PHOSPHATE,N/A,17,40,24,23,61,RO-may_prevent,820352-FS1,All persons with MALARIA receive 600 mg CHLOROQUINE PHOSPHATE at the clinic (day 0) and a prescription for another 600 mg for day 1 and 300 mg on day 2.,MALARIA,CHLOROQUINE PHOSPHATE
788860338,9/15/2015 20:58:15,1739006420,9/15/2015 20:57:39,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],ALS RILUZOLE,prevent,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:01:53,1739010767,9/15/2015 21:01:28,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:02:32,1739011527,9/15/2015 21:02:15,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment of,N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:02:51,1739011943,9/15/2015 21:02:15,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],RILUZOLE treatment ALS,treatment,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:08:41,1739017705,9/15/2015 21:08:23,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",effects of,n/a,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:16:39,1739026051,9/15/2015 21:16:14,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:16:40,1739026061,9/15/2015 21:15:36,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:32:50,1739035586,9/15/2015 21:32:35,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:36:19,1739037459,9/15/2015 21:35:19,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[TREATS],[TREATS],treatment,n/a,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:36:48,1739037702,9/15/2015 21:36:17,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],clarifying the biological effects,n/a,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:42:04,1739040472,9/15/2015 21:40:07,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS] [CONTRAINDICATES],"[TREATS]
[CONTRAINDICATES]",treatment,N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 21:44:00,1739041573,9/15/2015 21:43:34,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[PREVENTS] [CAUSES] [IS_A] [NONE],"[PREVENTS]
[CAUSES]
[IS_A]
[NONE]",[PREVENTS],N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 22:13:48,1739053969,9/15/2015 22:12:20,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],RILUZOLE in the treatment of ALS,n/a,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 22:15:40,1739054562,9/15/2015 22:15:10,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860338,9/15/2015 22:16:40,1739054970,9/15/2015 22:15:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],RILUZOLE in treatment of ALS,na,143,219,146,145,227,RO-may_treat,820078-FS1,The outcome of magnetic resonance spectroscopic studies assessing the ability of riluzole to retard the rate of neuronal loss in patients with ALS may be of considerable interest in clarifying the biological effects of RILUZOLE in the treatment of ALS (4).,ALS,RILUZOLE
788860339,9/16/2015 01:35:21,1739124221,9/16/2015 01:35:09,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 01:55:43,1739142717,9/16/2015 01:55:29,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],effect,n/a,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:00:53,1739146654,9/16/2015 01:59:30,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],conducted,N/A,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:04:00,1739149242,9/16/2015 02:03:23,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],treatment,n/a,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:22:11,1739164896,9/16/2015 02:21:47,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:45:39,1739186500,9/16/2015 02:45:06,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[SIDE_EFFECT] [LOCATION] [SYMPTOM] [NONE],"[LOCATION]
[SYMPTOM]
[SIDE_EFFECT]
[NONE]",DVSD,YHYTH YHJYTHJ,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:51:08,1739191809,9/16/2015 02:50:37,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[TREATS],[TREATS],ACYCLOVIR,N/A,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:57:21,1739197502,9/16/2015 02:57:09,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:57:59,1739197928,9/16/2015 02:56:50,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:58:45,1739198607,9/16/2015 02:58:27,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 02:59:23,1739199236,9/16/2015 02:57:51,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,herpes zoster's pain is treated by acyclovir,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 03:20:48,1739218373,9/16/2015 03:20:25,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HERPES ZOSTER,NONE,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 03:25:00,1739222538,9/16/2015 03:24:24,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS],[TREATS],the treatment of,N/A,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 03:37:45,1739234530,9/16/2015 03:36:20,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],treatment,N/A,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860339,9/16/2015 03:56:26,1739251747,9/16/2015 03:55:29,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],for the treatment of,n/a,139,218,152,151,227,RO-may_prevent,820232-FS1,"Meta analysis of four double blind, randomized, placebo controlled trials of oral acyclovir (800 mg five times daily) for the treatment of HERPES ZOSTER was conducted to provide definitive assessments of the effect of ACYCLOVIR on the resolution of zoster associated pain.",HERPES ZOSTER,ACYCLOVIR
788860340,9/15/2015 21:08:53,1739017776,9/15/2015 21:08:24,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],HYDROCORTISONE ADRENAL FAILURE,treat,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:10:44,1739019799,9/15/2015 21:10:27,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],starting therapy with,N/A,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:11:07,1739020117,9/15/2015 21:10:45,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],the clinical evolution,n/a,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:11:33,1739020667,9/15/2015 21:10:53,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"favourable,",N/A,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:22:01,1739029438,9/15/2015 21:20:29,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]","clinical evolution favourable, ADRENAL FAILURE irreversible.",there is relation,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:40:56,1739039946,9/15/2015 21:40:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,There's no relation between the terms.,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:43:22,1739041192,9/15/2015 21:42:53,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],starting therapy,n/a,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:44:17,1739041723,9/15/2015 21:43:58,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[CAUSES],[CAUSES],therapy,n/a,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:53:03,1739045929,9/15/2015 21:52:37,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[CAUSES] [TREATS] [OTHER] [PART_OF] [NONE],"[TREATS]
[CAUSES]
[PART_OF]
[OTHER]
[NONE]",[PREVENTS],N/A,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 21:56:12,1739047254,9/15/2015 21:55:32,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],therapy,N/A,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 22:22:40,1739057083,9/15/2015 22:22:28,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],starting therapy,n/a,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 22:26:00,1739057970,9/15/2015 22:25:43,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],and HYDROCORTISONE although ADRENAL FAILURE,n/a,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 22:30:57,1739059704,9/15/2015 22:30:01,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],starting therapy with,N/A,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 22:35:05,1739061130,9/15/2015 22:32:44,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYDROCORTISONE ADRENAL FAILURE,na,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860340,9/15/2015 22:45:37,1739064574,9/15/2015 22:45:25,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[TREATS],[TREATS],therapy,n/a,147,84,163,161,98,RO-may_treat,820118-FS1,"After immediate discontinuation of heparin and starting therapy with danaparoid and HYDROCORTISONE the clinical evolution was favourable, although ADRENAL FAILURE was irreversible.",ADRENAL FAILURE,HYDROCORTISONE
788860341,9/15/2015 20:56:12,1739004159,9/15/2015 20:55:33,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[SYMPTOM],[SYMPTOM],IDIOPATHIC URTICARIA LORATADINE,treat,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 20:59:55,1739008378,9/15/2015 20:59:31,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],management of,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:00:06,1739008609,9/15/2015 20:59:42,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[PREVENTS],[PREVENTS],prevent,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:00:15,1739008821,9/15/2015 20:59:14,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[PREVENTS] [SYMPTOM],"[PREVENTS]
[SYMPTOM]",self medication chronic IDIOPATHIC URTICARIA,not prevent,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:06:15,1739015731,9/15/2015 21:05:25,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH] [NONE] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]
[NONE]",medication,n/a,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:11:24,1739020427,9/15/2015 21:10:17,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],does not prevent,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:13:23,1739022551,9/15/2015 21:12:57,false,instagc,1.0,20312760,GBR,O1,Dukinfield,2.96.59.31,[CONTRAINDICATES],[CONTRAINDICATES],does not prevent,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:15:05,1739024619,9/15/2015 21:14:37,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[OTHER],[OTHER],does not prevent,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:30:08,1739034113,9/15/2015 21:29:20,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],importance of understanding,n/a,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:31:33,1739034913,9/15/2015 21:30:55,false,neodev,1.0,30504276,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],management,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:34:27,1739036415,9/15/2015 21:33:25,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],self medication,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:35:10,1739036839,9/15/2015 21:34:45,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],does not prevent,n/a,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:41:36,1739040221,9/15/2015 21:41:17,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[CAUSES] [SYMPTOM] [IS_A] [NONE],"[CAUSES]
[SYMPTOM]
[IS_A]
[NONE]",[PREVENTS],N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 21:47:58,1739043688,9/15/2015 21:47:47,false,prodege,1.0,2143114,CAN,BC,Vancouver,24.85.153.181,[PREVENTS],[PREVENTS],management,n/a,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860341,9/15/2015 22:12:24,1739053465,9/15/2015 22:10:20,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],does not prevent,N/A,68,132,101,97,142,RO-may_treat,820082-FS1,"70 ,   73 ,   76 •  For  self medication  for management of chronic IDIOPATHIC URTICARIA (EG HIVES importance of understanding that LORATADINE does not  prevent  hives.",IDIOPATHIC URTICARIA (EG HIVES,LORATADINE
788860342,9/16/2015 01:57:29,1739144062,9/16/2015 01:57:18,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[TREATS],[TREATS],relieved,n/a,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 02:03:31,1739148870,9/16/2015 02:02:34,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],relieved,N/A,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 02:07:00,1739151897,9/16/2015 02:06:26,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[PREVENTS],[PREVENTS],relieved,n/a,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 02:23:22,1739165839,9/16/2015 02:23:09,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],relieved,N/A,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 02:48:13,1739188991,9/16/2015 02:47:48,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[NONE]",UHUIH,LOÑK BHB,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 02:55:50,1739196121,9/16/2015 02:55:01,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],ASPIRIN,N/A,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 02:59:34,1739199425,9/16/2015 02:59:15,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],relieved,N/A,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 03:02:39,1739202184,9/16/2015 03:02:15,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 03:03:41,1739203056,9/16/2015 03:03:15,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,Aspirin treats pain,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 03:05:37,1739205020,9/16/2015 03:05:24,false,neodev,1.0,34431172,USA,NY,New York,162.243.160.236,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 03:24:41,1739222322,9/16/2015 03:23:49,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[PREVENTS],[PREVENTS],ASPIRIN,NONE,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 03:29:33,1739226740,9/16/2015 03:28:38,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[SYMPTOM],[SYMPTOM],was relieved by in six cases only.,N/A,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 03:39:55,1739236605,9/16/2015 03:39:41,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],relieved,N/A,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 04:01:09,1739255922,9/16/2015 04:00:18,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS],[PREVENTS],was relieved by,n/a,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860342,9/16/2015 04:01:58,1739256778,9/16/2015 04:01:41,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[TREATS],[TREATS],PAIN relieved by ASPIRIN,N/A,4,25,8,7,32,RO-may_prevent,820241-FS1,The PAIN was relieved by ASPIRIN in six cases only.,PAIN,ASPIRIN
788860343,9/16/2015 03:07:05,1739206336,9/16/2015 03:06:43,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 03:12:56,1739211315,9/16/2015 03:12:26,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 03:33:14,1739230184,9/16/2015 03:32:24,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],ARRHYTHMIAS,NONE,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 03:37:02,1739233823,9/16/2015 03:36:15,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",TREATMENT have been reported.,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 03:44:42,1739241200,9/16/2015 03:44:08,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],susceptibility to and,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 04:06:25,1739260738,9/16/2015 04:06:01,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 04:11:01,1739264931,9/16/2015 04:10:16,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],have been reported.,n/a,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 04:18:34,1739272404,9/16/2015 04:18:06,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[MANIFESTATION] [SIDE_EFFECT] [NONE],"[MANIFESTATION]
[SIDE_EFFECT]
[NONE]",none,none,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 04:38:26,1739292524,9/16/2015 04:35:37,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [SIDE_EFFECT],"[SIDE_EFFECT]
[NONE]",have been reported,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 05:14:48,1739329790,9/16/2015 05:14:17,false,elite,1.0,29216801,USA,"","",172.164.36.118,[PART_OF],[PART_OF],and,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 05:17:04,1739332016,9/16/2015 05:16:42,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],TREATMENT,n/a,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 05:25:23,1739339709,9/16/2015 05:23:44,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[PART_OF],[PART_OF],susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT,n/a,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 05:28:01,1739342504,9/16/2015 05:26:51,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 05:56:22,1739374776,9/16/2015 05:55:23,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],susceptibility,N/A,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860343,9/16/2015 05:57:46,1739376454,9/16/2015 05:57:22,false,neodev,1.0,34429821,USA,CA,San Jose,50.118.172.120,[NONE],[NONE],[NONE],[NONE] because n,64,80,75,74,104,RO-may_prevent,820362-FS1,Sexual dimorphisms of atherosclerosis and the susceptibility to ARRHYTHMIAS and ANTIARRHYTHMIC TREATMENT have been reported.,ARRHYTHMIAS,ANTIARRHYTHMIC TREATMENT
788860344,9/16/2015 03:04:53,1739204345,9/16/2015 03:04:29,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[SIDE_EFFECT],[SIDE_EFFECT],effective,Side effect,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 03:10:14,1739209039,9/16/2015 03:08:55,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had levels of,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 03:28:23,1739225465,9/16/2015 03:27:45,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SYMPTOM],[SYMPTOM],MALARIA 53,NONE,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 03:33:19,1739230249,9/16/2015 03:32:49,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[SYMPTOM],[SYMPTOM],with symptoms of,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 03:42:42,1739239149,9/16/2015 03:42:22,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had levels,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 04:04:23,1739258915,9/16/2015 04:04:03,false,gifthunterclub,1.0,30901412,GBR,G5,Margate,85.210.116.48,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptoms of MALARIA ordinarily effective levels CHLOROQUINE,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 04:06:18,1739260576,9/16/2015 04:05:33,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],with symptoms of,n/a,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 04:16:41,1739270525,9/16/2015 04:16:22,false,neodev,1.0,33373894,USA,MI,Ann Arbor,35.2.200.96,[LOCATION] [MANIFESTATION] [ASSOCIATED_WITH] [NONE],"[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[NONE]",nothing,vnothing,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 04:29:07,1739282324,9/16/2015 04:28:49,false,elite,1.0,33798502,USA,VA,Manassas,207.244.79.135,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",ordinarily effective levels,It makes sense,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 04:29:26,1739282709,9/16/2015 04:28:05,false,clixsense,1.0,6363498,USA,GA,Fort Valley,23.125.3.6,[NONE] [SYMPTOM],"[SYMPTOM]
[NONE]",symptoms of,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 04:52:00,1739306464,9/16/2015 04:51:36,false,neodev,1.0,33739744,USA,VA,Manassas,207.244.83.121,[NONE] [OTHER],"[OTHER]
[NONE]",N/a,I did not find any relationship,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 05:11:45,1739326702,9/16/2015 05:10:11,false,clixsense,1.0,19294877,USA,MA,Boston,71.174.187.97,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 05:12:34,1739327494,9/16/2015 05:12:11,false,elite,1.0,29216801,USA,"","",172.164.36.118,[SYMPTOM],[SYMPTOM],symptoms,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 05:15:23,1739330389,9/16/2015 05:15:00,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],ordinarily effective,n/a,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860344,9/16/2015 05:18:09,1739333039,9/16/2015 05:16:18,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had ordinarily effective levels of CHLOROQUINE,N/A,57,109,64,63,120,RO-may_prevent,820242-FS1,Among 56 subjects reporting to a clinic with symptoms of MALARIA 53 (95%) had ordinarily effective levels of CHLOROQUINE in blood.,MALARIA,CHLOROQUINE
788860345,9/15/2015 21:06:52,1739016308,9/15/2015 21:06:12,false,neodev,1,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],Among 3618 FLUORIDE CARIES DMFT,treat,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:09:59,1739018885,9/15/2015 21:09:23,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,[CAUSES],[CAUSES],were CARIES free,N/A,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:10:27,1739019478,9/15/2015 21:09:50,false,neodev,1,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CARIES,N/A,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:14:16,1739023727,9/15/2015 21:13:56,false,clixsense,1,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",and the mean,n/a,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:19:39,1739028101,9/15/2015 21:18:42,false,clixsense,1,32053717,GBR,"","",51.174.76.80,[LOCATION],[LOCATION],"FLUORIDE areas (Gadag),",location,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:39:21,1739039119,9/15/2015 21:37:40,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],high FLUORIDE areas CARIES free,N/A,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:42:35,1739040784,9/15/2015 21:42:03,false,neodev,1,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],living in high,n/a,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:43:32,1739041324,9/15/2015 21:43:11,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,[PREVENTS],[PREVENTS],CARIES free,n/a,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:51:52,1739045485,9/15/2015 21:51:25,false,neodev,1,33701549,NLD,"","",85.203.17.204,[PREVENTS] [TREATS] [SYMPTOM] [IS_A] [PART_OF] [NONE],"[TREATS]
[PREVENTS]
[SYMPTOM]
[IS_A]
[PART_OF]
[NONE]",[PREVENTS],N/A,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 21:55:05,1739046818,9/15/2015 21:53:11,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Among,N/A,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 22:22:09,1739056892,9/15/2015 22:21:48,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[PREVENTS],[PREVENTS],CARIES free,n/a,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 22:25:00,1739057741,9/15/2015 22:24:38,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"groups, living in high FLUORIDE were CARIES free",n/a,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 22:29:40,1739059265,9/15/2015 22:29:14,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,[PREVENTS],[PREVENTS],CARIES free,N/A,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 22:30:36,1739059620,9/15/2015 22:29:41,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FLUORIDE were CARIES free,na,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860345,9/15/2015 22:42:01,1739063388,9/15/2015 22:41:31,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[NONE],[NONE],none,n/a,91,58,97,96,66,RO-may_prevent,820243-FS1,"Among 3618 children of similar age groups, living in high FLUORIDE areas (Gadag), 84% were CARIES free and the mean DMFT value was 0.39.",CARIES,FLUORIDE
788860346,9/15/2015 21:00:55,1739009604,9/15/2015 21:00:19,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[MANIFESTATION],[MANIFESTATION],BECLOMETHASONE ASTHMA,cares,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:04:15,1739013472,9/15/2015 21:03:53,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:04:34,1739013863,9/15/2015 21:04:20,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment of,N/A,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:08:31,1739017543,9/15/2015 21:07:28,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",treatment rhinitis ASTHMA side effects.,treatment/. but psbl side effects,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:10:10,1739019106,9/15/2015 21:09:57,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],in the,n/a,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:18:22,1739027398,9/15/2015 21:18:04,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[TREATS],[TREATS],treatment,N/A,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:23:40,1739030352,9/15/2015 21:22:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:38:21,1739038547,9/15/2015 21:38:04,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],treatment,n/a,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:39:35,1739039228,9/15/2015 21:39:21,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:46:21,1739042823,9/15/2015 21:45:56,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[TREATS] [CAUSES] [ASSOCIATED_WITH] [NONE],"[TREATS]
[CAUSES]
[ASSOCIATED_WITH]
[NONE]",[PREVENTS],N/A,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 21:46:57,1739043171,9/15/2015 21:46:27,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 22:18:01,1739055492,9/15/2015 22:16:21,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],BECLOMETHASONE DIPROPIONATE in treatment of ASTHMA,n/a,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 22:18:54,1739055801,9/15/2015 22:18:41,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 22:20:12,1739056239,9/15/2015 22:19:25,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860346,9/15/2015 22:21:59,1739056874,9/15/2015 22:20:57,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],BECLOMETHASONE DIPROPIONATE in treatment of ASTHMA,na,166,105,172,171,132,RO-may_prevent,820364-FS1,Long term animal studies of beclomethasone dipropionate and of budesonide and a few long term studies of BECLOMETHASONE DIPROPIONATE in the treatment of rhinitis and ASTHMA are available for the assessment of the possible risk of side effects.,ASTHMA,BECLOMETHASONE DIPROPIONATE
788860347,9/15/2015 23:48:06,1739084090,9/15/2015 23:47:51,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[MANIFESTATION] [PREVENTS] [SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [NONE] [IS_A],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[IS_A]
[NONE]",", Harper RW, Harrison PM et al. Pharmacokinetic interaction bet",", Harper RW, Harrison PM et al. Pharmacokinetic interaction bet",110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 00:16:55,1739091410,9/16/2015 00:16:20,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[SIDE_EFFECT]",interaction between and verapamil,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 01:04:45,1739105238,9/16/2015 01:03:46,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",for,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 01:16:06,1739112617,9/16/2015 01:15:14,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[TREATS],[TREATS],for,n/a,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 01:32:49,1739122553,9/16/2015 01:32:37,false,elite,1.0,30659615,USA,"","",162.250.145.234,[LOCATION],[LOCATION],between,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 01:41:19,1739131769,9/16/2015 01:40:16,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[TREATS],[TREATS],interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 01:52:57,1739140565,9/16/2015 01:52:25,false,elite,1.0,30659677,USA,"","",162.252.172.126,[LOCATION],[LOCATION],between,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 01:53:00,1739140592,9/16/2015 01:52:48,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],and,n/a,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 01:56:58,1739143718,9/16/2015 01:56:37,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],interaction,n/a,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 02:17:35,1739160635,9/16/2015 02:16:48,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],Pharmacokinetic interaction between oral METOPROLOL verapamil for ANGINA,contraindicates,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 02:19:26,1739162327,9/16/2015 02:18:18,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 02:40:06,1739181031,9/16/2015 02:39:35,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[TREATS] [PREVENTS] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[OTHER]
[NONE]",JUN,NIUN BYG,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 02:42:52,1739183767,9/16/2015 02:42:16,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[PREVENTS],[PREVENTS],METOPROLOL,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 02:48:40,1739189547,9/16/2015 02:48:29,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],between,N/A,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860347,9/16/2015 02:52:40,1739193265,9/16/2015 02:51:22,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,Metoprolol treats angina pectoris,110,81,125,124,91,RO-may_treat,820001-FS1,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
788860348,9/15/2015 21:04:43,1739014064,9/15/2015 21:04:08,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],HYPOPARATHYROIDISM VITAMIN D,prevent,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:07:04,1739016409,9/15/2015 21:06:30,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[CAUSES],[CAUSES],cause,N/A,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:08:21,1739017386,9/15/2015 21:07:35,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[CAUSES],[CAUSES],cause of the deficit of,N/A,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:13:16,1739022402,9/15/2015 21:12:46,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[CAUSES],[CAUSES],cause,n/a,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:16:18,1739025733,9/15/2015 21:14:59,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[SYMPTOM],[SYMPTOM],HYPOPARATHYROIDISM deficit VITAMIN D,symptom of deficit vit. D,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:21:16,1739029019,9/15/2015 21:21:03,false,elite,1.0,30312592,CAN,ON,Sudbury,66.103.55.12,[CAUSES],[CAUSES],cause,N/A,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:34:47,1739036620,9/15/2015 21:34:00,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],and,N/A,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:40:53,1739039897,9/15/2015 21:40:25,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:42:15,1739040573,9/15/2015 21:41:54,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[CAUSES],[CAUSES],cause,n/a,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:49:45,1739044490,9/15/2015 21:49:15,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [NONE] [OTHER],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[OTHER]
[NONE]",[PREVENTS],N/A,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 21:50:43,1739044980,9/15/2015 21:50:20,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],cause,N/A,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 22:20:55,1739056461,9/15/2015 22:20:41,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CAUSES],[CAUSES],cause deficit,n/a,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 22:23:32,1739057304,9/15/2015 22:22:57,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[CAUSES],[CAUSES],HYPOPARATHYROIDISM cause deficit of VITAMIN D,n/a,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 22:26:06,1739057993,9/15/2015 22:24:57,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CAUSES],[CAUSES],cause of,N/A,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860348,9/15/2015 22:28:02,1739058624,9/15/2015 22:27:17,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],HYPOPARATHYROIDISM and cause of deficit of VITAMIN D,na,87,138,105,104,147,RO-may_treat,820123-FS1,Controversial is the pathogenesis of the absence of hypocalcemia in many patients with HYPOPARATHYROIDISM and the cause of the deficit of VITAMIN D,HYPOPARATHYROIDISM,VITAMIN D
788860349,9/15/2015 21:11:22,1739020398,9/15/2015 21:10:35,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],SEIZURES MAGNESIUM SULFATE,treat,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:13:14,1739022359,9/15/2015 21:12:53,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],occurred,N/A,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:15:56,1739025388,9/15/2015 21:15:45,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurred in patients,n/a,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:23:37,1739030310,9/15/2015 21:23:15,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[CAUSES],[CAUSES],levels were in the therapeutic range.,N/A,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:26:13,1739031711,9/15/2015 21:25:36,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[TREATS],[TREATS],SEIZURES MAGNESIUM SULFATE therapeutic,treatment,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:44:59,1739042054,9/15/2015 21:44:45,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[SYMPTOM],[SYMPTOM],in whom,n/a,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:45:26,1739042325,9/15/2015 21:45:12,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[CAUSES],[CAUSES],occurred,n/a,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:46:05,1739042706,9/15/2015 21:44:19,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[CAUSES],[CAUSES],occurred in patients in whom,N/A,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:54:54,1739046764,9/15/2015 21:54:26,false,neodev,1.0,33701549,NLD,"","",85.203.17.204,[TREATS] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[PREVENTS],N/A,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 21:59:17,1739048781,9/15/2015 21:58:29,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurred in,N/A,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 22:23:55,1739057444,9/15/2015 22:23:39,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurred,n/a,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 22:27:17,1739058411,9/15/2015 22:27:04,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[SYMPTOM],[SYMPTOM],SEIZURES occurred in patients whom MAGNESIUM SULFATE levels,n/a,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 22:34:08,1739060799,9/15/2015 22:33:30,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CAUSES],[CAUSES],occurred in,N/A,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 22:38:06,1739062214,9/15/2015 22:37:34,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in range.,na,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860349,9/15/2015 22:44:03,1739064043,9/15/2015 22:43:32,false,clixsense,1.0,28457001,CAN,ON,North Bay,24.204.202.220,[SIDE_EFFECT],[SIDE_EFFECT],occurred,n/a,5,43,13,12,60,RO-may_prevent,820366-FS1,Some SEIZURES occurred in patients in whom MAGNESIUM SULFATE levels were in the therapeutic range.,SEIZURES,MAGNESIUM SULFATE
788860350,9/16/2015 01:35:35,1739124363,9/16/2015 01:35:23,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],reduced,N/A,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 01:56:21,1739143217,9/16/2015 01:55:44,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],reduced,n/a,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:01:11,1739146877,9/16/2015 02:00:55,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],reduced,N/A,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:04:39,1739149862,9/16/2015 02:04:01,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[TREATS],[TREATS],use,n/a,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:22:24,1739165064,9/16/2015 02:22:13,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],reduced,N/A,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:46:12,1739186961,9/16/2015 02:45:42,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[SYMPTOM] [CAUSES] [NONE],"[CAUSES]
[SYMPTOM]
[NONE]",BGHB,GHBVGB WSE,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:51:52,1739192475,9/16/2015 02:51:13,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[OTHER],[OTHER],GASTRIC,N/A,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:58:03,1739198024,9/16/2015 02:57:26,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],reduced,N/A,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:58:12,1739198138,9/16/2015 02:58:03,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 02:59:06,1739199042,9/16/2015 02:58:46,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],reduced,Tteat,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 03:00:26,1739200111,9/16/2015 02:59:24,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,misoprostol is a treatment for the ulcers,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 03:21:08,1739218707,9/16/2015 03:20:49,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],arthritis,NONE,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 03:26:07,1739223568,9/16/2015 03:25:05,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[CONTRAINDICATES],[CONTRAINDICATES],whether it is cost effective,N/A,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 03:38:05,1739234792,9/16/2015 03:37:46,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[TREATS],[TREATS],reduced,N/A,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860350,9/16/2015 03:57:05,1739252349,9/16/2015 03:56:27,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS],[PREVENTS],reduced by,n/a,40,80,68,67,91,RO-may_prevent,820245-FS1,The absence of firm data on the rate of NSAID INDUCED GASTRIC ULCERS reduced by MISOPROSTOL makes it impossible to conclude whether it is cost effective in patients with chronic arthritis who use NSAIDS.,NSAID INDUCED GASTRIC ULCERS,MISOPROSTOL
788860351,9/15/2015 23:44:39,1739083227,9/15/2015 23:44:22,false,neodev,1.0,33228343,USA,"","",208.31.49.57,[PREVENTS] [PART_OF] [OTHER] [CAUSES] [CONTRAINDICATES] [MANIFESTATION] [NONE],"[PREVENTS]
[CAUSES]
[MANIFESTATION]
[CONTRAINDICATES]
[PART_OF]
[OTHER]
[NONE]",bad,"he risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD G",12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 00:07:21,1739089205,9/16/2015 00:06:23,false,elite,1.0,31722487,USA,NJ,East Brunswick,69.248.85.124,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[IS_A]","lower with this regimen,",N/A,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 00:53:47,1739100360,9/16/2015 00:53:19,false,bitcoinget,1.0,28503763,USA,CA,San Francisco,107.217.186.64,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 00:57:31,1739101504,9/16/2015 00:56:37,false,clixsense,1.0,11106820,USA,MA,Taunton,173.48.52.95,[MANIFESTATION],[MANIFESTATION],"lower with this regimen,",n/a,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 01:24:41,1739117535,9/16/2015 01:23:32,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NOCTURNAL HYPOGLYCEMIA and FASTING BLOOD GLUCOSE better controlled.,associated with,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 01:26:52,1739119005,9/16/2015 01:24:28,false,neodev,1.0,20233773,USA,CA,San Jose,173.245.65.163,[PREVENTS],[PREVENTS],"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE","the risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE",12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 01:29:46,1739120584,9/16/2015 01:29:34,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],lower,N/A,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 01:44:03,1739133921,9/16/2015 01:43:50,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],lower,N/A,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 01:45:47,1739135197,9/16/2015 01:45:24,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[PREVENTS],[PREVENTS],controlled.,n/a,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 01:48:33,1739137309,9/16/2015 01:48:20,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],lower,N/A,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 01:50:06,1739138544,9/16/2015 01:49:47,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],and,n/a,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 02:15:43,1739158825,9/16/2015 02:15:31,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],lower,N/A,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 02:31:30,1739173051,9/16/2015 02:31:05,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],lower,N/A,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 02:32:14,1739173710,9/16/2015 02:30:53,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",FASTING BLOOD GLUCOSE,n/a,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860351,9/16/2015 02:33:36,1739174903,9/16/2015 02:31:19,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [CAUSES] [PREVENTS] [TREATS] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[NONE]",hui,any the lol,12,67,34,33,88,RO-may_treat,820004-FS1,"The risk of NOCTURNAL HYPOGLYCEMIA is lower with this regimen, and FASTING BLOOD GLUCOSE is better controlled.",NOCTURNAL HYPOGLYCEMIA,FASTING BLOOD GLUCOSE
788860352,9/16/2015 01:34:53,1739123974,9/16/2015 01:34:36,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],resulting,N/A,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 01:55:13,1739142292,9/16/2015 01:54:52,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[CAUSES],[CAUSES],resulting in,n/a,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 01:59:14,1739145392,9/16/2015 01:57:00,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],resulting,N/A,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:02:30,1739147910,9/16/2015 02:01:56,false,points4rewards,1.0,20306700,USA,WA,Bothell,50.106.46.70,[CAUSES],[CAUSES],resulting,n/a,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:21:30,1739164170,9/16/2015 02:21:17,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],resulting,N/A,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:44:20,1739185303,9/16/2015 02:43:50,false,neodev,1.0,31984900,AUS,02,Sydney,103.238.131.248,[MANIFESTATION] [CAUSES] [SYMPTOM] [NONE],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[NONE]",FVSDV,DSVDS WEFWE,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:49:11,1739190070,9/16/2015 02:48:32,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.48,[PREVENTS],[PREVENTS],INSULIN,N/A,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:52:50,1739193348,9/16/2015 02:52:01,false,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],INSULIN release resulting in HYPERGLYCEMIA,manifestation,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:53:50,1739194315,9/16/2015 02:53:21,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],resulting,N/A,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:56:32,1739196702,9/16/2015 02:56:22,false,neodev,1.0,34431172,USA,NY,New York,192.81.213.117,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:57:09,1739197238,9/16/2015 02:55:38,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,hyperglycemia occurs when insulin is inhibited,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 02:57:53,1739197857,9/16/2015 02:57:34,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],reduces,Treat,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 03:19:55,1739217625,9/16/2015 03:19:25,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[CAUSES],[CAUSES],HYPERGLYCEMIA,NONE,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 03:23:35,1739221232,9/16/2015 03:22:59,false,points4rewards,1.0,28703583,USA,"","",184.53.32.159,[CAUSES],[CAUSES],resulting in,N/A,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
788860352,9/16/2015 03:34:51,1739231670,9/16/2015 03:34:13,false,clixsense,1.0,21665495,CAN,"","",24.105.69.70,[SIDE_EFFECT],[SIDE_EFFECT],resulting,N/A,138,92,151,150,99,RO-may_treat,820005-FS1,"a •  Increases glycogenolysis in the liver, reduces glucose uptake by tissues, and inhibits INSULIN release in the pancreas, resulting in HYPERGLYCEMIA",HYPERGLYCEMIA,INSULIN
